Medicare Part D Prescription Drug Benefit

Suzanne M. Kirchhoff
Analyst in Health Care Financing

August 13, 2018
Summary

The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA; P.L. 108-173) established a voluntary, outpatient prescription drug benefit under Medicare Part D, effective January 1, 2006. Medicare Part D provides coverage through private prescription drug plans (PDPs) that offer only drug coverage, or through Medicare Advantage (MA) prescription drug plans (MA-PDs) that offer coverage as part of broader, managed care plans. Private drug plans participating in Part D bear some financial risk, although federal subsidies cover most program costs in an effort to encourage participation and keep benefits affordable.

At a minimum, Medicare drug plans must offer a “standard coverage” package of benefits or alternative coverage that is actuarially equivalent to a standard plan. Plans also may offer enhanced benefits. Although all plans must meet certain minimum requirements, there can be significant differences among offerings in terms of benefit design, specific drugs included in formularies (i.e., list of covered drugs), cost sharing for particular drugs, or the level of monthly premiums. In general, beneficiaries can enroll in a plan, or change plan enrollment, when they first become eligible for Medicare or during open enrollment periods each October 15 through December 7. For plan year 2018, there are between 19 and 26 PDPs in the nation’s 34 PDP regions, in addition to Medicare Advantage plans. Because sponsors are allowed to change plan offerings from year to year, beneficiaries annually face the need for careful review of their choices to select the plans that best meet their needs.

A key element of the Part D program is enhanced coverage for low-income individuals. Persons with incomes up to 150% of the federal poverty level (FPL) and assets below set limits are eligible for extra assistance with Medicare Part D premiums and cost sharing. Individuals enrolled in both Medicare and Medicaid (so-called dual eligibles) and certain other low-income beneficiaries are automatically enrolled in no-premium plans, which are Part D plans that have premiums at or below specified levels.

In 2017, about 42.5 million out of a total of 58.6 million Medicare beneficiaries received prescription drug benefits through a PDP or an MA-PD, with almost one-third receiving a low-income subsidy. Another 1.6 million received drug assistance through a Part D-subsidized retiree health plan. Of the remaining 25% of Medicare beneficiaries not enrolled in Part D, about half had coverage through health care plans that was at least as generous as Part D; the other half had no coverage or coverage less generous than Part D. Overall, about 88% of Medicare beneficiaries had drug coverage through either PDP or MA-PD plans, retiree coverage, or private insurance of comparable scope. Total Part D expenditures were approximately $100.0 billion in calendar year 2017.

Medicare Part D has cost less than originally forecasted, due in part to lower-than-predicted enrollment and increased use of less expensive generic drugs. However, the Medicare Trustees project that spending on Part D benefits will accelerate over the next 10 years due to the expectation of further increases in the number of enrollees, costs associated with the gradual elimination of the out-of-pocket cost coverage gap, changes in the distribution of enrollees among coverage categories, a slowing of the trend toward greater generic drug utilization, and an increase in the use and the prices of specialty drugs.
# Contents

Overview .................................................................................................................. 1  
Eligibility.................................................................................................................. 2  
  Eligibility for Low-Income Assistance ................................................................. 3  
  Full-Subsidy-Eligible Individuals ..................................................................... 4  
  Other-Subsidy-Eligible Individuals ................................................................ 5  
  Changes in LIS Status ......................................................................................... 6  
Enrollment in Part D .............................................................................................. 6  
  Enrollment Periods ............................................................................................ 6  
    Initial Enrollment Period .................................................................................. 7  
    Annual Open Enrollment Period .................................................................... 7  
    Special Enrollment Periods ............................................................................ 7  
  Late Enrollment Penalty ..................................................................................... 8  
  Plan Selection .................................................................................................... 8  
  Plan Marketing .................................................................................................. 10  
Enrollment Process ............................................................................................... 11  
  LIS Enrollment .................................................................................................. 12  
  Auto-Enrollment .............................................................................................. 12  
  Facilitated Enrollment ....................................................................................... 12  
  Reassignment of Certain LIS Beneficiaries ..................................................... 13  
Part D Benefit Structure ...................................................................................... 13  
  Premiums .......................................................................................................... 14  
    Premium Surcharge for Higher-Income Enrollees ........................................ 15  
  Qualified Drug Coverage .................................................................................. 17  
    Standard Prescription Drug Coverage ......................................................... 17  
The Coverage Gap ................................................................................................. 19  
  Phaseout of the Coverage Gap ......................................................................... 20  
  True Out-of-Pocket Costs ................................................................................. 23  
Low-Income Subsidies ......................................................................................... 25  
  Premium Assistance .......................................................................................... 25  
    Full-Subsidy-Eligible Individuals ................................................................ 25  
    Partial-Subsidy-Eligible Individuals ................................................................. 25  
  Cost-Sharing Subsidies ..................................................................................... 26  
Employer Subsidies ............................................................................................... 27  
  Retiree Drug Subsidy ......................................................................................... 28  
  Employer Group Waiver Plans ......................................................................... 28  
Drug Coverage ....................................................................................................... 29  
  Drugs Covered by Other Parts of Medicare ...................................................... 30  
Formularies ........................................................................................................... 30  
  Formulary Categories and Classes ................................................................ 31  
  Six Classes of Clinical Concern ........................................................................ 31  
  Vaccines ............................................................................................................ 32  
  Plan-Year Formulary Changes ........................................................................ 32  
  Transition Policies ............................................................................................. 33  
Drug Utilization Management Programs ............................................................ 34
Tiered Formularies .................................................................................................................. 34
Other Drug Utilization Controls .............................................................................................. 35
Part D Opioid Overutilization Monitoring .............................................................................. 35
Medication Therapy Management .......................................................................................... 37
Part D Plans: Payment and Participation .................................................................................. 37
  Approval of PDP Plans ............................................................................................................ 38
    Noninterference Provision ..................................................................................................... 39
  Plan Availability ..................................................................................................................... 39
  Availability of Low-Income Plans ......................................................................................... 39
  Plan Payments ....................................................................................................................... 39
    Direct Subsidies .................................................................................................................. 40
    Reinsurance Subsidies .......................................................................................................... 40
    Risk Corridor Payments ...................................................................................................... 40
    Reconciliation ...................................................................................................................... 42
  Reduction of Part D Plan Payments Under Sequestration ..................................................... 43
Pharmacy Access and Payment ............................................................................................... 43
  Any Willing Pharmacy ........................................................................................................... 43
  Preferred Pharmacy .............................................................................................................. 44
  Retail Pharmacy Access ....................................................................................................... 44
  Mail-Order Pharmacy Access ............................................................................................... 45
  Specialty Pharmacy Access ................................................................................................... 45
  Long-Term Care Pharmacy Access ....................................................................................... 46
  Home Infusion Pharmacy Access ......................................................................................... 46
  Out-of-Network Access ........................................................................................................ 46
  Payments to Pharmacies ....................................................................................................... 47
Coverage Determinations, Appeals, and Grievances ............................................................... 47
  Coverage Determination ....................................................................................................... 48
  Appeals ................................................................................................................................. 48
    Redetermination ................................................................................................................ 48
    Reconsideration by an Independent Review Entity ............................................................ 49
    Additional Levels of Appeal ............................................................................................... 49
    Standard Hearing ............................................................................................................... 50
  Grievances ............................................................................................................................ 50
  Quality of Care Complaints .................................................................................................... 50
Program Oversight .................................................................................................................. 51
  CMS Oversight ..................................................................................................................... 51
  Oversight Responsibilities of Part D Sponsors ....................................................................... 52
  Medicare Part D Oversight Contractors ............................................................................... 52
    Medicare Drug Integrity Contractor: National Benefit Integrity ......................................... 52
    Medicare Drug Integrity Contractor: Outreach and Education ........................................... 52
    Part D Recovery Audit Contractor ...................................................................................... 53
Program Spending and Financing ............................................................................................ 53
  Expenditures ........................................................................................................................ 53
  Revenues ............................................................................................................................... 53
    Beneficiary Premiums ......................................................................................................... 54
    General Revenues ............................................................................................................... 55
    State Contributions ............................................................................................................. 55
  Historical Program Spending ............................................................................................... 56
Estimated Future Part D Expenditures

Figures

Figure 1. Annual Part D Base Beneficiary Monthly Premium
Figure 2. 2018 Standard Medicare Prescription Drug Benefit
Figure 3. Closing the Doughnut Hole for Brand-Name Drugs in 2019
Figure 4. Closing the Doughnut Hole for Brand and Generic Drugs

Tables

Table 1. Total Medicare Beneficiaries with Prescription Drug Coverage, 2017
Table 2. Medicare Part D Low-Income Subsidy Enrollment
Table 3. Overview of How Medicare Beneficiaries Qualify for LIS
Table 4. 2018 Monthly Medicare Part D High-Income Surcharge
Table 5. Closing the Doughnut Hole
Table 6. Sliding-Scale Premium for Partial-Subsidy-Eligible Individuals
Table 7. Part D Standard Benefits, 2018
Table 8. Plan Liability Under Part D Risk Corridor Provisions
Table 9. Medicare Part D Risk Corridor Payments
Table 10. Statement of Operations of Part D Account, CY2017
Table 11. Comparison of Projected and Actual Part D Enrollment and Spending
Table 13. Historical and Projected Growth in Part D Benefits
Table 14. Medicare Part D Reimbursement Amounts
Table A-1. Operation of the Part D Account in the SMI Trust Fund, CY2004-CY2027

Appendixes

Appendix. Historical and Projected Part D Operations

Contacts

Author Contact Information
Overview

On January 1, 2018, the Medicare outpatient prescription drug benefit (Medicare Part D) began its 13th year of operation. Congress created Part D in the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA; P.L. 108-173), effective January 1, 2006. The law also made Part D the primary source of drug coverage for individuals covered under both Medicare and Medicaid, (so-called dual eligibles). Since that time, Part D has been modified by a series of statutes, including by the Patient Protection and Affordable Care Act of 2010 as amended (ACA; P.L. 111-148; P.L. 111-152).1

Part D coverage is provided through private insurance plans (PDPs) that offer only drug coverage, or through Medicare Advantage (MA) plans (MA-PDs) that offer drug coverage as part of a broader, Medicare Part C managed care benefit. Alternatively, beneficiaries may be enrolled in retiree prescription drug plans offered by their former employers. The MMA provides subsidies for retiree drug plans as an incentive to employers to continue such plans. (See “Retiree Drug Subsidy.”) A growing number of employers and unions are also offering retirees (and their eligible spouses and dependents) Part D benefits through employer-group waiver plans (EGWPs). See “Employer Group Waiver Plans.”)

As of July 2018, 44.2 million Medicare beneficiaries were enrolled in Part D plans. Of that total, about 25.5 million were in PDPs, 18.0 million were in MA-PDs, and about 690,000 were in other types of plans.2

A major focus of the Part D program is providing subsidized coverage to qualified, low-income beneficiaries. Individuals with incomes up to 150% of the federal poverty level and limited assets are eligible for a low-income subsidy (LIS). The LIS reduces beneficiaries’ out-of-pocket spending by paying for all, or some, of the Part D monthly premium and annual deductible, and limiting co-payments or coinsurance. The LIS is progressive, meaning the lowest-income beneficiaries receive the greatest assistance. An estimated 12.9 million beneficiaries will receive the LIS in 2018.3

The ACA made major changes to Part D in an effort to improve coverage and to make the premium structure more progressive, including requiring higher-income beneficiaries to pay more for coverage. Starting in 2011, the ACA required Part D enrollees with incomes above a certain threshold to pay a monthly surcharge in addition to their regular plan premiums. (See “Premium Surcharges for High Income Enrollees.”) In addition, the ACA phases out the “doughnut hole” by requiring drug manufacturers to provide discount for brand-name drugs purchased by

beneficiaries in the Part D coverage gap, or “doughnut hole” and gradually phases in Medicare subsidies to cover 75% of the cost of generic drugs and 25% of the cost of brand name drugs in the coverage gap. (See “The Coverage Gap.”) The ACA provisions were further modified by the Medicare Access and CHIP Reauthorization Act (MACRA; P.L. 114-10) and the Balanced Budget Act of 2018 (BBA 2018; P.L. 115-123), which, among other things, accelerated the closing of the coverage gap.

Medicare Part D relies on participating private insurance plans to provide coverage and bear part of the financial risk of the program. All Part D plans must meet certain minimum requirements, though there are significant variations among plans in terms of benefit design including differences in premiums, drug formularies (i.e., lists of covered drugs), and cost sharing for particular drugs. In 2018, a total of 782 PDPs are offered nationwide, an increase of 36 (or 5%) from 2017 but a 12% reduction from 2016. Medicare beneficiaries have 23 PDPs and 17 MA-PDs to choose from in their geographic area, on average.

Eligibility

In general, anyone who is entitled to Medicare Part A and/or enrolled in Part B is eligible to enroll in a Medicare Part D drug plan. In addition, an individual must be a U.S. citizen or qualified alien and must permanently reside within one of the 34 designated PDP regions in the United States; anyone who is living abroad or is incarcerated is not eligible.

For most people, joining Part D is voluntary, although dual-eligible beneficiaries (See “Full-Subsidy-Eligible Individuals”) are automatically enrolled. Medicare beneficiaries cannot be turned down for Part D coverage due to pre-existing health conditions or high utilization of prescription drugs.

Of the 58.6 million Medicare beneficiaries in 2017 who were eligible for Part D, 42.5 million (72.5%) were enrolled in a Part D plan and another 1.6 million (2.7%) had prescription drug coverage through a former employer that received a Part D subsidy for a portion of their coverage. Of the remaining 25% of Medicare beneficiaries, about half had drug coverage as generous as Part D through another source, such as the Federal Employees Health Benefits program, TRICARE, or private coverage. The remaining 12.5% of Medicare beneficiaries either had less generous coverage than Part D or no drug coverage at all. (See Table 1.)

---

4 The coverage gap refers to the period when a Medicare beneficiary has exceeded a drug plan’s standard payment threshold and faces higher out-of-pocket expenses until he or she reaches an annual catastrophic threshold. Once the catastrophic threshold is reached, federal subsidies cover most prescription costs and enrollees pay a maximum of 5% coinsurance.


Table 1. Total Medicare Beneficiaries with Prescription Drug Coverage, 2017

<table>
<thead>
<tr>
<th>Description</th>
<th>Number of Medicare Beneficiaries (in millions)</th>
<th>Percentage of Eligible Beneficiaries</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medicare Beneficiaries Eligible for Part D</td>
<td>58.6</td>
<td>100%</td>
</tr>
<tr>
<td>Medicare Part D</td>
<td>42.5</td>
<td>72.5%</td>
</tr>
<tr>
<td>Stand-Alone PDP</td>
<td>25.1</td>
<td>59%</td>
</tr>
<tr>
<td>MA with Drug Coverage</td>
<td>17.4</td>
<td>41%</td>
</tr>
<tr>
<td>Medicare Retiree Drug Subsidy (RDS)</td>
<td>1.6</td>
<td>2.7%</td>
</tr>
<tr>
<td>Other Creditable Drug Coverage</td>
<td>7.3</td>
<td>12.5%</td>
</tr>
<tr>
<td><strong>Total Beneficiaries with Drug Coverage</strong></td>
<td><strong>49.3</strong></td>
<td><strong>87.5%</strong></td>
</tr>
<tr>
<td>Beneficiaries Without Equivalent Coverage</td>
<td>7.3</td>
<td>12.5%</td>
</tr>
</tbody>
</table>


Note: Totals may not add due to rounding.

Eligibility for Low-Income Assistance

Beneficiaries with limited incomes and resources may qualify for assistance with their Part D premiums, cost sharing, and other out-of-pocket expenses. In 2018, a forecast 12.9 million Medicare beneficiaries received low-income subsidies (LIS). (See Table 2 below.)

Table 2. Medicare Part D Low-Income Subsidy Enrollment (in millions)

<table>
<thead>
<tr>
<th>Year</th>
<th>Medicaid, Full-Benefit Dual Eligible</th>
<th>Other, with Full Subsidy</th>
<th>Other, with Partial Subsidy</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>2006</td>
<td>5.7</td>
<td>2.3</td>
<td>0.2</td>
<td>8.3</td>
</tr>
<tr>
<td>2007</td>
<td>5.9</td>
<td>3.0</td>
<td>0.3</td>
<td>9.2</td>
</tr>
<tr>
<td>2008</td>
<td>6.3</td>
<td>3.2</td>
<td>0.3</td>
<td>9.7</td>
</tr>
<tr>
<td>2009</td>
<td>6.4</td>
<td>3.3</td>
<td>0.3</td>
<td>10.0</td>
</tr>
<tr>
<td>2010</td>
<td>6.6</td>
<td>3.5</td>
<td>0.3</td>
<td>10.4</td>
</tr>
<tr>
<td>2011</td>
<td>6.6</td>
<td>3.7</td>
<td>0.3</td>
<td>10.6</td>
</tr>
<tr>
<td>2012</td>
<td>6.9</td>
<td>3.7</td>
<td>0.3</td>
<td>11.0</td>
</tr>
<tr>
<td>2013</td>
<td>7.2</td>
<td>4.0</td>
<td>0.3</td>
<td>11.5</td>
</tr>
<tr>
<td>2014</td>
<td>7.4</td>
<td>4.1</td>
<td>0.3</td>
<td>11.8</td>
</tr>
<tr>
<td>2015</td>
<td>7.5</td>
<td>4.2</td>
<td>0.3</td>
<td>12.1</td>
</tr>
<tr>
<td>2016</td>
<td>7.8</td>
<td>4.3</td>
<td>0.3</td>
<td>12.4</td>
</tr>
<tr>
<td>2017</td>
<td>7.9</td>
<td>4.4</td>
<td>0.3</td>
<td>12.7</td>
</tr>
<tr>
<td>2018</td>
<td>8.0</td>
<td>4.6</td>
<td>0.3</td>
<td>12.9</td>
</tr>
</tbody>
</table>

Source: 2016 and 2018 Medicare Trustees Reports, Table IV.B7.

Notes: Figures are for calendar years. Totals may not add due to rounding.
Full-Subsidy-Eligible Individuals

Certain groups of Medicare beneficiaries automatically qualify (and are deemed eligible) for the full low-income subsidy. So-called full benefit dual eligibles who qualify for Medicaid based on income and assets are automatically deemed eligible for Medicare prescription drug low-income subsidies. Additionally, those who receive premium and/or cost-sharing assistance from Medicaid through the Medicare Savings Program (MSP), plus those eligible for Supplemental Security Income (SSI) cash assistance, are automatically deemed eligible for full low-income subsidies. This group includes all eligible persons who (1) have incomes below 135% of the federal poverty level, or $16,389 for an individual and $22,221 for a couple in 2018; (2) have resources below $7,560 for an individual and $11,340 for a couple in 2018. The limits are increased annually by the percentage increase in the Consumer Price Index (CPI). (See Table 3.)

The Centers for Medicare & Medicaid Services (CMS) deems individuals automatically eligible for LIS effective as of the first day of the month that they attain qualifying status (e.g., become eligible for Medicaid or SSI). The end date is, at a minimum, through the end of the calendar year within which the individual becomes eligible. Beneficiaries who are deemed LIS-eligible for any month during the period of July through December of one year are deemed eligible through the end of the following calendar year. CMS changes an individual’s deemed status in mid-year only when such a change qualifies the beneficiary for a reduced co-payment obligation.

Eligibility for the LIS is not always continuous from year to year. For example, LIS beneficiaries who lose eligibility for Medicaid or SSI during the year are not automatically qualified to receive the LIS the next year. Each September, CMS is to notify such individuals that their LIS-deemed status will end on December 31 of that year. Such individuals may reapply for the LIS, as they may qualify for the LIS through the application process. (See “LIS Enrollment.”)

At the end of each plan year, CMS reassigns LIS beneficiaries who are enrolled in Part D plans if their plan is terminated or raises its monthly premium to a level above the LIS benchmark premium for the plan region. The ACA altered the method for determining which Part D plans are eligible to enroll low-income beneficiaries so that more plans can qualify and, thus, reduce the

---

8 The Medicare Savings Program includes the Qualified Medicare Beneficiary program (QMB), Specified Low-Income Medicare Beneficiary program (SLMB), and Qualifying Individual program (QI). These programs help Medicare beneficiaries of modest means pay all or some of Medicare’s cost-sharing amounts (i.e., premiums, deductibles, and co-payments). To qualify, an individual must be eligible for Medicare and must meet certain income limits which change annually.

9 Supplemental Security Income (SSI) is a federal income supplement program funded by general tax revenues (not Social Security taxes). It is designed to help aged, blind, and disabled people who have little or no income, and it provides cash to meet basic needs for food, clothing, and shelter.


11 In addition, program resource limits provide for a $1,500 burial allowance. SSA, “HI 03030.025, Resource Limits for Subsidy Eligibility,” at https://secure.ssa.gov/poms.nsf/fnx/0603030025.

number of low-income beneficiaries who are reassigned from year to year. According to CMS, 279,419 LIS beneficiaries enrolled in PDP plans and 91,419 in MA-PDs were reassigned for the 2017 plan year.

Table 3. Overview of How Medicare Beneficiaries Qualify for LIS

<table>
<thead>
<tr>
<th>LIS Eligibility</th>
<th>Beneficiaries Who Have</th>
<th>Basis</th>
<th>Data Used to Determine Eligibility</th>
<th>Changes During the Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>Full-Subsidy Eligibility</td>
<td>• Full Medicaid benefits</td>
<td></td>
<td>State Files</td>
<td>• Qualify for a full calendar year.</td>
</tr>
<tr>
<td></td>
<td>• Medicare Savings Program assistance</td>
<td>Automatically qualify for LIS</td>
<td>SSA</td>
<td>• Generally only favorable changes will occur within a year.</td>
</tr>
<tr>
<td></td>
<td>• SSI benefits</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Partial-Subsidy Eligibility</td>
<td>• Limited Income and Resources</td>
<td>Must apply for LIS</td>
<td>SSA (almost all) or states</td>
<td>• Some events can impact status during a year.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Subsidies can increase, decrease, or terminate during a year.</td>
</tr>
</tbody>
</table>

Source: CRS table based on Social Security Administration (SSA) and CMS data.

Other-Subsidy-Eligible Individuals

Other individuals with limited incomes and resources who do not automatically qualify may apply for the low-income subsidy and have their eligibility determined by either the Social Security Administration (SSA) or their state Medicaid agency. This group includes all other persons who (1) are enrolled in a PDP plan or MA-PD plan; (2) have incomes below 150% of the federal poverty level, $18,210 for an individual and $24,690 for a couple in 2018; and (3) have assets below $12,600 for an individual and $25,150 for a couple in 2018 (increased in future years by the percentage increase in the CPI). An individual who applies, and is deemed eligible for the LIS, is allowed to begin receiving benefits on the first day of the month in which the application was submitted. In most cases, this means that LIS status is applied retroactively. For example, if an LIS beneficiary was enrolled in a Part D plan prior to a determination of LIS eligibility, the Part D sponsor must ensure that the beneficiary is reimbursed for any premiums or cost sharing that should have been covered by the subsidy. If a person wasn’t already eligible for Medicare, the LIS subsidy takes effect on the first day of the month when his or her Medicare eligibility begins.


Initial LIS eligibility determinations are for no longer than 12 months. If the SSA or a state Medicaid agency later decides that an individual is no longer eligible for the LIS, that same entity also decides when the LIS benefits end. The end date is always the last day of a calendar month, though it may occur in any month of the year.

Changes in LIS Status

LIS determinations are also reviewed in the case of certain developments that could affect the amount of the subsidy. Throughout each plan year, CMS uses SSA data and state Medicare Modernization Act files to initiate the eligibility process for new recipients, and look for any changes in eligibility status for current, low-income beneficiaries.\(^\text{17}\)

The ACA created new rules for LIS redeterminations subsequent to the death of a spouse. Beginning in 2011, the surviving spouse of an LIS-eligible couple receives a grace period for the determination or redetermination of benefits.\(^\text{18}\) For example, after the death of her spouse, a widow would fill out and send a Part D redetermination form to CMS. After CMS reviews the document,

- if the information indicates that the widow qualifies for a more generous subsidy or has a more favorable resources level for purposes of LIS calculations, the change would take effect in the month following the month when the redetermination report was received;
- if the information indicates no change in status, the widow would not be sent a redetermination form the following year (with some exceptions); and
- if the information indicates a need to reduce the LIS, or provides a less favorable resources level, the redetermination would be postponed.

Enrollment in Part D

Enrollment Periods

A Medicare beneficiary who is signing up for Part D for the first time\(^\text{19}\) may do so in one of three different enrollment periods, depending on the individual’s circumstances:

- Initial Enrollment Period for Part D;
- Annual Open Enrollment Period (or Annual Coordinated Election Period, AEP); or
- Special Enrollment Period (SEP).


Individuals who qualify for LIS may enroll at any time.

**Initial Enrollment Period**

The initial enrollment period is the time during which an individual is first eligible to enroll in a Part D plan. Beneficiaries not yet enrolled in Medicare may join a drug plan at any time during their seven-month initial Medicare enrollment period. The Part D initial enrollment period is the same as the initial enrollment period for Medicare Part B. Coverage for new enrollees begins on the first day of the month following the month of enrollment, but no earlier than the first month they are entitled to Medicare.

Individuals who become eligible for Medicare but have “creditable” coverage, which is prescription drug coverage that CMS estimates will provide at least the same level of benefits as Medicare’s standard prescription drug package, may choose not to sign up for Part D during the initial enrollment period. Sources of possible creditable coverage include some employer-based prescription drug coverage, including the Federal Employees Health Benefits Program; qualified State Pharmaceutical Assistance programs (SPAPs); and military-related coverage (e.g., VA, TRICARE). However, these individuals could face a penalty if they let their creditable coverage lapse before enrolling in Part D. (See “Late Enrollment Penalty.”)

**Annual Open Enrollment Period**

In general, an individual who does not sign up for Part D during his or her initial enrollment period may enroll only during the annual open enrollment period, held from October 15 to December 7 each year. Coverage then begins the following January 1. Beneficiaries already enrolled in a Part D plan may change their plans during the annual open enrollment period.

Beneficiaries may wish to change plans for a variety of reasons, including changes in their health status and prescription drug needs or in response to modifications by their plans. Generally, sponsors make changes to plan benefits effective at the beginning of each calendar year. After the open enrollment period closes, most beneficiaries are locked into their Part D plans for the upcoming benefit year.

**Special Enrollment Periods**

There are limited occasions besides the annual open enrollment period when an individual may enroll in, or dis-enroll from, a Part D plan or switch from one Part D plan to another. These special enrollment periods (SEPs) are open to individuals who (1) move to a new geographic area, (2) involuntarily lose creditable coverage, (3) receive inadequate information about their creditable coverage status, (4) are subject to a federal error, or (5) are enrolled in a PDP that has failed or has been terminated.

---


22 This includes being released from jail or out of an institution.

Late Enrollment Penalty

A late enrollment penalty is assessed on persons who go without creditable drug coverage for 63 continuous days or more after the close of their initial enrollment period, and then sign up for Part D. The penalty is intended to encourage wider enrollment and prevent adverse selection, which can occur when healthy people put off buying insurance while those with a real or perceived need immediately enroll. If Part D enrollees are mainly those who are ill or have higher prescription drug costs, per-capita program costs can rise. Higher prices, in turn, may cause other enrollees (presumably healthier, less costly ones) to end coverage. Over time, if more persons drop out, program costs could become prohibitive.

The Part D late penalty is based on the number of months an individual does not have creditable coverage. The penalty is calculated by multiplying 1% of the national base premium ($35.02 in 2018) by the number of full months an individual has been eligible but has gone without coverage. The final amount is rounded to the nearest $0.10. For example, if a beneficiary was eligible for Part D in June 2016 but did not sign up until the 2018 open enrollment period, and did not have creditable coverage during the 30-month interim period, the individual would pay an additional $10.50 per month.

The late penalty is applied permanently to Part D premiums. Because the national base premium is recalculated annually, and the penalty is based on the base premium, the penalty amount will increase in subsequent years if the base premium rises. Dual-eligible and other LIS beneficiaries are not subject to the late enrollment penalty.

Plan Selection

Sponsors can alter a plan benefit package at the beginning of a new program year, including changing the mix of drugs in a formulary and/or modifying required cost sharing for certain drugs. Sponsors must mail an Annual Notice of Change (ANOC) to enrollees each year, to be delivered by September 30. The document describes any modifications to the plan’s premiums, drug coverage, cost sharing, and other features for the coming benefit year. The delivery deadline is designed to ensure that beneficiaries have at least two weeks to review the information prior to October 15, the first day of the annual enrollment period.

Sponsors are required to send beneficiaries other enrollment-related materials and information such as the Summary of Benefits and Evidence of Coverage documents. These documents offer

---

24 The late enrollment penalty is calculated based on the national base beneficiary premium, not the premium of the enrollee’s plan. Therefore, the penalty is billed to applicable enrollees even if the plan’s Part D basic premium is $0.


26 CMS, “Part D Late Enrollment Penalty?,” at http://www.medicare.gov/part-d/costs/penalty/part-d-late-enrollment-penalty.html. (To calculate, 1% × 30 months equals 0.30, and $35.02 × 0.30 equals $10.506. The amount is then rounded to $10.50.)

27 Starting in 2019, the time frame for delivery of the annual Evidence of Coverage (EOC) information will be moved to the first day of the Annual Election Period (AEP), rather than fifteen days prior to that date. In addition, Part D plans will be allowed to deliver more documents, including the EOC, by notifying enrollees that the documents have been posted on the Internet. Enrollees will have the right to request hard copies. CMS, “Medicare Program: Contract Year 2019 Policy and Technical Changes to Medicare Advantage, Medicare Cost Plan, Medicare Fee-for-Service, Medicare Prescription Drug Benefit Programs, and PACE Program,” 83 Federal Register, April 16, 2018, p. 16621; at https://www.gpo.gov/fdsys/pkg/FR-2018-04-16/pdf/2018-07179.pdf.
information about a plan’s formulary, general utilization management and pricing policies, information on beneficiary rights, and other information.

Each year, Medicare beneficiaries face the need to review the cost of their current drug and health plans, (if in MA) including premiums, co-payments, and deductibles, and compare the cost and coverage to other plans in their area. Additionally, beneficiaries can examine whether plans have price tiers that increase or decrease the price of the drugs they use, whether the plans offer preferred pharmacy options, and what, if any, utilization management requirements the plans impose for drugs. (See “Drug Utilization Management Programs.”)

CMS posts information on its open enrollment web page to help beneficiaries compare Part D plan prices.28 Beneficiaries, and persons assisting them, can also use the Medicare drug plan finder.29 After a beneficiary enters information into the plan finder regarding medications being used, the dosages, and the pharmacy he or she plans to use, the plan finder displays Part D plans in the area that cover those particular drugs.30 The plan finder also provides information on quality ratings to make it easier to compare plans based on cost, quality, and performance ratings.31 CMS will send notices to beneficiaries in low-quality plans encouraging them to look at other, higher rated plans. (See “Low-Quality Plans.”)

Information on plan availability and characteristics can be obtained from a number of additional sources, including the Medicare toll-free information number (1-800-MEDICARE), State Health Insurance Assistance Programs (SHIPs),32 and other local organizations.

Low-Quality Plans

CMS uses a star-rating system to assess the quality of Part D plans. MA-PD sponsors are rated on up to 48 quality and performance measures, while PDP sponsors are assessed on up to 14 measures.33 Plans are ranked on a scale of one to five stars, with five stars considered excellent. By CMS practice, Part D Sponsors must provide star rating information to beneficiaries through a standard document that must be distributed with enrollment information and prominently posted on plan websites.

---

30 For example, a plan with the lowest premium and/or no deductible may end up not being the lowest cost plan for the beneficiary if the total cost sharing (including any deductible, co-payments, or coinsurance) for the beneficiary’s specific drugs is more than under a different plan.
31 The plans are rated on how well they perform in different categories, including (1) drug plan customer service, (e.g., how long members wait on hold and how frequently they meet deadlines for timely appeals); (2) member complaints and number of beneficiaries staying with the same drug plan; (3) member satisfaction with drug plans; and (4) drug pricing and patient safety, including how often drug plans update their prices and formulary information on the Medicare website and how similar a drug plan’s estimated prices on the Medicare website are to prices members pay at the pharmacy.
32 SHIPs are state-based programs that use community-based networks to provide Medicare beneficiaries with local personalized assistance on a wide variety of Medicare and health insurance topics and receive federal funding for their activities. See http://www.medicare.gov/contacts.
CMS has determined that three stars is the lowest acceptable quality rating for a plan. Plans must display a special icon if they have a star rating of 2.5 or lower for three years of data. Plans with star ratings of less than three stars for three consecutive years may be terminated by CMS. In addition, CMS may disable the online enrollment function for plans with a low-rating icon and beneficiaries will be directed to contact the plan directly to enroll in the low-performing plan. Plans that receive five-star ratings may display a special icon recognizing them as high-performing plans. Part D enrollees are provided with a special enrollment period during which they can switch to a five-star plan, provided they meet other enrollment requirements.

### Plan Marketing

Plan sponsors are required to provide timely and accurate information in their marketing materials. Since the implementation of Part D in 2006, plans have been required to submit all marketing materials to CMS for review. Starting in 2019, a smaller share of annual plan materials provided to enrollees and prospective enrollees will be subject to CMS prior review. Under revised rules, CMS is to classify activities and materials used to provide information to enrollees and prospective enrollees as communications. Marketing will be a subset of plan communications and will be defined, in part, as activities and the use of materials that are likely to lead a beneficiary to make an enrollment decision. For example, communications materials issued by a plan sponsor that simply described a Part D sponsor organization but did not include information about a plan’s benefit structure, costs, or star ratings, would not be marketing information and would not be subject to prior review. A brochure issued by a plan sponsor that touted the benefits of joining a specific Part D plan and spelled out benefits and cost sharing would be considered marketing material and would be subject to review.

In general, Medicare rules are designed to ensure that beneficiaries have complete and accurate information when making decisions about drug plans. For example, a plan that has received a four-star rating for one of the services it provides, but a three-star quality rating overall, cannot create promotional material stating that the plan is a four-star plan. Plans must use a standardized

---

34 A contract receives a low performing icon as a result of its performance on Part C or Part D ratings. The low performing icon is calculated by evaluating the Part C and Part D summary ratings for the current year and the past two years. If the contract had any combination of Part C or Part D summary ratings of 2.5 or lower in all three years of data, it is marked with a low performing icon.


names and materials across their service region and must receive prior agreement from plan enrollees to provide certain information in a format other than a mailing.39 Plans are not allowed to market via unsolicited contacts, such as door-to-door sales. There are also limits on marketing and sales events. All plan sponsors must have interpreters in their call centers to translate for people who are not proficient in English.40

Plans are required to provide certain documents upon request or enrollment, such as a summary of benefits, the plan formulary, and a directory of contracting pharmacies. Plan sponsors may offer nominal gifts (worth $15 or less) to potential enrollees, though they may not take the form of cash or rebates.41

**Enrollment Process**

Beneficiaries can join a Part D plan in a variety of ways including (1) filling out a paper application; (2) visiting a plan’s website and enrolling online; (3) using the Medicare online enrollment center at http://www.medicare.gov; (4) calling the company offering the drug plan; or (5) calling 1-800-MEDICARE. In general, a PDP sponsor cannot deny a valid enrollment request from any Part D-eligible individual residing in its service area.

An individual (or his/her legal representative) must complete an enrollment request, and include all the information required to process the enrollment. Upon receiving an enrollment request, a PDP sponsor must provide, within 10 calendar days, (1) a notice of acknowledgement of receipt of the beneficiary’s application, (2) a request for more information in cases of incomplete applications, or (3) a notice that the application has been denied, along with an explanation of the reasons why.

Prior to the effective date of enrollment, under CMS rules, a plan sponsor must provide necessary information about being a member of the PDP, including the PDP rules and the member’s rights and responsibilities. In addition, the PDP sponsor must provide the following: a copy of the completed enrollment form, if needed; a notice acknowledging receipt of the enrollment request providing the expected effective date of enrollment; and proof of health insurance coverage so that a beneficiary may begin using the plan services as of the effective date. For all enrollment requests, the PDP sponsor must submit the information necessary for CMS to add the beneficiary to its records as an enrollee of the PDP sponsor within seven calendar days of receipt of the complete enrollment request.

---

39 Ibid., Section 40.9. Plans may provide provider and/or pharmacy directories electronically without prior consent from an enrollee. Under Section 60.4, Part D plans may (1) send enrollees the plan formulary in hard copy, which may be abridged, or (2) send a distinct and separate notice (in hard copy) describing where enrollees can find the formulary online and how enrollees can request a hard copy formulary.

40 Ibid., Section 80.1. The interpreters should be available within eight minutes of reaching a call center.

41 Ibid.


43 Medicare drug plan participation in Medicare’s online enrollment center is voluntary, so not all Medicare drug plans will offer this option.
LIS Enrollment

Special enrollment rules apply to low-income individuals. Generally, there is a two-step process for low-income persons to gain Part D coverage. First, a determination must be made that they qualify for the assistance; second, they must enroll, or be enrolled, in a specific Part D plan.

LIS enrollees have been allowed to change plans at any time during the plan year, unlike other Part D enrollees who generally may switch plans only during the annual enrollment period at the end of the year. Starting in 2019, LIS enrollees will no longer be allowed an open-ended, monthly SEP. Instead, LIS enrollees will be allowed an SEP once per calendar quarter during the first nine months of the year and also will be eligible for SEPs (1) within three months after the start of coverage or notification that they have been enrolled by CMS or a state in a Part D plan and (2) within three months after a change to their LIS or Medicaid status. The rules also place limits on SEPs for LIS enrollees who are identified by CMS as at risk of opioid abuse. (See “Part D Opioid Overutilization Monitoring”)

Auto-Enrollment

Full-benefit, dual-eligible individuals who have not elected a Part D plan are automatically enrolled into one by CMS. CMS first uses data provided by state Medicaid agencies to identify full-benefit, dual-eligible individuals. CMS then identifies plan sponsors that offer at least one Part D plan in the region offering basic prescription drug coverage with a premium at or below the low-income premium subsidy amount. If more than one sponsor in a region meets the criteria, CMS auto-enrolls beneficiaries on a random basis among available PDP sponsors. CMS next identifies individual plans offered by the sponsor that include basic drug coverage with premiums at or below the low-income premium subsidy amount. The beneficiary is then randomly assigned among the sponsor’s plans meeting the criteria.

If an individual is not eligible to enroll in a PDP because he or she is enrolled in a Medicare Advantage plan (other than a MA private-fee-for-service plan [MA-PFFS] that does not offer Part D, or a medical savings account [MSA] plan), CMS is to direct the MA organizations to facilitate the enrollment of these individuals into an MA-PD plan offered by the same MA organization.

Some dual-eligible beneficiaries may find that they have been auto-enrolled in a plan that may not best meet their needs. For this reason, they are provided with more opportunities to change enrollment, with the new coverage effective the following month. (See “LIS Enrollment.”) If an enrollee selects a plan with a premium above the low-income benchmark, however, he or she is required to pay the difference.

Facilitated Enrollment

CMS established a process labeled “facilitated enrollment” for enrollees in Medicare Savings programs (MSPs), SSI enrollees, and persons who applied for and were approved for low-income subsidy assistance. The basic features applicable to auto-enrollment for dual eligibles (i.e.,

---


46 Full-benefit duals who live in another country, live in one of the five U.S. territories, are inmates in a correctional facility, have already enrolled in a Part D plan, or have opted out of auto-enrollment into a Part D plan, are excepted from this process.
identification of eligibility through SSA and/or Medicaid data, random assignment to plans with premiums below the low-income benchmark, and assignment of MA enrollees to the lowest-cost MA-PD plan offered by the MA organization) are the same for facilitated enrollment.

Reassignment of Certain LIS Beneficiaries

Drug plans may increase premiums at the beginning of a plan year, in some cases raising them above the benchmark for LIS beneficiaries. When that is the case, CMS is to reassign certain LIS recipients to different plans so they can continue to receive benefits without paying Part D premiums (or continue paying only a minimal amount). CMS may also automatically reassign LIS recipients if their current plan terminates operations. LIS beneficiaries who have voluntarily changed plans in previous years are not automatically reassigned by CMS, even if their plans charge premiums above the benchmark. LIS beneficiaries in MA-PD plans are automatically reassigned to PDP plans if their current plan ceases operations or they are affected by a reduction in the plan’s service area.

About 1.16 million LIS beneficiaries were enrolled in benchmark PDPs in 2016 that had terminated or did not qualify as benchmark plans in 2017. CMS reassigned 279,419 beneficiaries to different PDPs. Another 879,260 million LIS beneficiaries were not reassigned because they had previously switched plans voluntarily.47

The ACA made changes to Part D in an effort to reduce the need for automatic reassignment of LIS beneficiaries.48 For instance, the law changed the methodology for calculating the benchmark premium for some plans. In addition, PDPs with premiums above LIS-eligible levels no longer have LIS beneficiaries reassigned if they voluntarily agree to waive a de minimis portion of the premium above the benchmark. However, such plans would not qualify to receive other LIS beneficiaries who are automatically reassigned from their current plans.49

Part D Benefit Structure

The MMA set out a standard prescription drug benefit structure. Plan sponsors may, and often do, offer different benefit designs and cost-sharing requirements, so long as they meet certain specifications. Under the standard benefit structure, with some exceptions, over the course of a year a beneficiary is responsible for paying (1) a monthly premium, (2) an annual deductible, and (3) co-payments or coinsurance for drug purchases. Additionally, for a certain period called the “coverage gap” (also known as the doughnut hole), beneficiaries face increased out-of-pocket costs. The ACA included provisions to gradually eliminate the coverage gap. (See “The Coverage Gap.”)

Actual costs to Part D beneficiaries vary from plan to plan depending on the benefit structure and coverage offered, the costs and amount of drugs they use, and the level of any additional assistance such as through a low-income subsidy.50

---

**Premiums**

The majority of beneficiaries enrolled in Part D pay monthly premiums for Part D coverage. On average, beneficiary premiums represent 25.5% of the cost of a standard Part D plan, as determined through annual bids submitted by insurers. (See “Standard Prescription Drug Coverage.”) The beneficiary premium does not cover costs for federal reinsurance or subsidies to low-income beneficiaries. The dollar amount of Part D premiums will vary by plan.

**Figure 1. Annual Part D Base Beneficiary Monthly Premium**

<table>
<thead>
<tr>
<th>Year</th>
<th>Premium</th>
</tr>
</thead>
<tbody>
<tr>
<td>2006</td>
<td>$0.00</td>
</tr>
<tr>
<td>2007</td>
<td>$0.00</td>
</tr>
<tr>
<td>2008</td>
<td>$0.00</td>
</tr>
<tr>
<td>2009</td>
<td>$0.00</td>
</tr>
<tr>
<td>2010</td>
<td>$0.00</td>
</tr>
<tr>
<td>2011</td>
<td>$0.00</td>
</tr>
<tr>
<td>2012</td>
<td>$0.00</td>
</tr>
<tr>
<td>2013</td>
<td>$0.00</td>
</tr>
<tr>
<td>2014</td>
<td>$0.00</td>
</tr>
<tr>
<td>2015</td>
<td>$0.00</td>
</tr>
<tr>
<td>2016</td>
<td>$0.00</td>
</tr>
<tr>
<td>2017</td>
<td>$0.00</td>
</tr>
<tr>
<td>2018</td>
<td>$0.00</td>
</tr>
</tbody>
</table>


*Notes:* Amounts reflect 25.5% of the annual average of participating drug plan bids to provide basic Part D benefits.

Beneficiary premiums are based on average bids submitted by participating drug plans for basic benefits (the base beneficiary premium) each year and are adjusted to reflect the difference between the standardized bid amount of the plan the beneficiary enrolls in and the nationwide average bid. In 2018, the base beneficiary monthly premium, 25.5% of the average bid amount, is $35.02. Base premiums from 2006 through 2018 are shown in Figure 1. Beneficiaries in plans with higher costs for standard coverage face higher-than-average premiums, while enrollees in lower-cost plans pay lower-than-average premiums for such coverage. Additionally, enrollees in MA-PD plans may have lower premiums if their plans choose to buy down, or reduce, the Part D premium. The monthly premium is applied to all persons enrolled in a specific plan, except

---

51 Medicare subsidizes 80% of each plan’s costs above a set catastrophic threshold. This additional assistance is called the reinsurance subsidy. (See “Reinsurance Subsidies.”)


53 Medicare Advantage plans that earn a Part C rebate (by having estimated costs for providing benefits that are less than the maximum possible Medicare payment) must spend that rebate on supplemental benefits, reduced cost sharing or reduced Part B or D premiums.
those who are receiving low-income subsidies or are subject to a late enrollment penalty. Beneficiaries may pay plans directly or have premiums deducted from their Social Security benefits. Higher-income beneficiaries pay a monthly premium surcharge.

**Premium Surcharge for Higher-Income Enrollees**

When Part D began in 2006, all beneficiaries enrolled in the same plan (except those receiving the low-income subsidy) were subject to the same premium. Beginning in 2011, the ACA required Part D enrollees with higher earnings to pay higher premiums. The ACA Part D requirements are similar to the income-based premium structure that was already in place for Medicare Part B. Part D beneficiaries who have a modified adjusted gross income (MAGI) above set thresholds are now assessed a special surcharge, referred to as an income-related monthly adjustment amount (IRMMA), in addition to their regular PDP or MA-PD plan premiums. According to the SSA, less than 5% of Medicare enrollees have been subject to the IRMMA.

The higher-income surcharge is calculated as the difference between the Medicare Part D base beneficiary premium (which represents 25.5% of the average national bid amount) and 35%, 50%, 65%, or 80% of the national average cost for providing Part D benefits, excluding federal reinsurance or subsidies. The surcharge is based on beneficiary income, with higher-income beneficiaries facing a larger surcharge. Because individual plan premiums vary, the law specifies that CMS calculate the Part D surcharge using the base premium, rather than each beneficiary’s individual premium amount. (See Table 4.)

---

54 Social Security deductions are limited to $300 per month, the *harm limit*. SSA, HI 03001.001, “Description of the Medicare Part D Prescription Drug Program,” at https://secure.ssa.gov/poms.nsf/lnx/0603001001.


56 The definition of *modified adjusted gross income* (MAGI) used for the calculation is the total of adjusted gross income and tax-exempt interest income. The income data is based on the most recent tax information that the Internal Revenue Service is able to provide the Social Security Administration. Generally, the tax information is from two years prior to the year for which the premium is being determined but not more than three years prior. Social Security Administration, *Medicare Premiums: Rules for Higher-Income Beneficiaries*, 2018, at http://www.ssa.gov/pubs/EN-05-10536.pdf. MAGI has more than one definition in federal tax law, with the definition varying based on the program or provision utilizing the concept. See CRS Report R43861, *The Use of Modified Adjusted Gross Income (MAGI) in Federal Health Programs*.

57 The income thresholds are the same as those used for calculating Medicare Part B premiums.


Table 4. 2018 Monthly Medicare Part D High-Income Surcharge

<table>
<thead>
<tr>
<th>If Annual Income in 2016 Was</th>
<th>Plan Premium</th>
</tr>
</thead>
<tbody>
<tr>
<td>File Individual Tax Return</td>
<td>File Joint Tax Return</td>
</tr>
<tr>
<td>$85,000 or less</td>
<td>$170,000 or less</td>
</tr>
<tr>
<td>Above $85,000 to $107,000</td>
<td>Above $170,000 to $214,000</td>
</tr>
<tr>
<td>Above $107,000 to $133,500</td>
<td>Above $214,000 to $267,000</td>
</tr>
<tr>
<td>Above $133,500 to $160,000</td>
<td>Above $267,000 to $320,000</td>
</tr>
<tr>
<td>Above $160,000</td>
<td>Above $320,000</td>
</tr>
</tbody>
</table>


Note: Income figures refer to modified adjusted gross income.

The ACA originally froze the income thresholds for the IRMMA through 2019. Section 402 of the MACRA maintained the freeze on the income thresholds for all income categories through 2017 and on the lower two high-income premiums tiers through 2019. Beginning in 2018, MACRA reduces the threshold levels for the two highest income tiers so that more beneficiaries will fall into the higher-percentage categories. Additionally, starting in 2020, the income thresholds for all income categories will be adjusted annually for inflation based on the 2019 income thresholds. This will, in effect, maintain the proportion of beneficiaries who pay the high-income premium.61

Section 53114 of BBA 2018 adds an additional high-income category beginning in 2019 for individuals with annual income of $500,000 or more or couples filing jointly with income of $750,000 or more. Enrollees with income equal to or exceeding these thresholds will pay premiums that cover 85% of the average per capita cost of the Part D benefits instead of 80%. The threshold for couples filing jointly in this new income tier will be calculated as 150% of the individual income level rather than 200% as in the other income tiers. This new top income threshold will be frozen through 2027 and will be adjusted annually for inflation starting in 2028 based on the CPI-U.62

The surcharge is calculated using a statutory formula that multiplies the base Part D premium by a set ratio.63 For 2018, the ratios are (35% – 25.5%)/25.5%; (50% – 25.5%)/25.5%; (65% – 25.5%)/25.5%, or (80% – 25.5%)/25.5%. For example, for 2018 (with a base premium of $35.02) the surcharge for an individual with a 2016 adjusted gross income between $133,500 and $160,000 would be calculated as

\[ \text{IRMMA} = 35.02 \times \frac{(65\% - 25.5\%)/25.5\%}{25.5\%} \]
\[ \text{IRMMA} = 35.02 \times 1.549 \]
\[ \text{IRMMA} = 54.24, \text{ rounded down to the nearest dime} = 54.20. \]

62 These threshold changes will also apply to Part B income-related monthly adjustments. See CRS Report R40082, Medicare: Part B Premiums.
63 Social Security Act §1860D-13(a)(7).
Beneficiaries pay the surcharge directly to the federal government, rather than to Part D plans. When applicable, IRMMA will be withheld from an enrollee’s monthly Social Security check, Railroad Retirement benefit, or federal pension payment, unless the benefit check is not sufficient for the purpose. If a beneficiary is directly billed for IRMAA, he or she has the option of paying through an electronic funds transfer or by other means.

Qualified Drug Coverage

Part D plan designs may vary, but all PDPs and MA-PDs must offer at least a minimum package of benefits. This minimum set, referred to as “qualified prescription drug coverage,” may include either a standard package of prescription drug coverage established by Medicare or an alternative package that is actuarially equivalent. Plans may also offer “enhanced” coverage that exceeds the value of standard coverage. Premiums for these enhanced plans are generally higher than for standard plans. MA organizations offering MA-coordinated care plans are required to offer at least one plan for the service area that includes drug coverage. The drug coverage can be either basic coverage or enhanced coverage.

Standard Prescription Drug Coverage

Under the standard Part D benefit, a beneficiary first pays a deductible ($405 in 2018). After the deductible has been met, the beneficiary is responsible for 25% of the cost of prescription drugs (with the plan covering the remaining 75%) up to the initial coverage limit ($3,750 in 2018). To reach the initial coverage limit in a 2018 standard plan, a beneficiary would pay the $405 deductible plus $836.25 in prescription costs, for total out-of-pocket costs of $1,241.25. The plan would pay the remaining $2,508.75. After the initial coverage threshold has been reached, a beneficiary enters the coverage gap or “doughnut hole” and is responsible for a larger share of prescription drugs costs until he or she accumulates $5,000 in total out-of-pocket costs in 2018 (for those not receiving the LIS) and reaches the catastrophic threshold. Total drug spending needed to move through the deductible, the initial coverage limit, and the coverage gap to the catastrophic threshold is estimated at about

---

64 In cases where an enrollee’s benefit payment check is not sufficient to have the IRMMA withheld, or if an enrollee is not receiving such benefits, the beneficiary must be billed directly for the IRMMA. See 42 C.F.R. §423.293.
69 For those receiving a low-income subsidy (who are not eligible for manufacturer discounts in the doughnut hole), the catastrophic threshold is $7,508.75. For beneficiaries eligible for the manufacturer discount, the threshold depends on the mix of brand name and generic drugs used; the average non-LIS threshold is about $8,417.60
$8,417.60,\textsuperscript{70} with a portion paid by the beneficiary, a portion covered by the plan, and a portion offset by manufacturer discounts for brand-name drugs. (See “The Coverage Gap.”)

**Figure 2. 2018 Standard Medicare Prescription Drug Benefit**

Source: Figure created by CRS based on data from CMS, “Announcement of Calendar Year (CY) 2018 Medicare Advantage Capitation Rates and Medicare Advantage and Part D Payment Policies and Final Call Letter,” April 3, 2017, Attachments IV and V.

Note: Beneficiaries above the catastrophic threshold pay the greater of a $3.35 co-payment for generic drugs and an $8.35 co-payment for brand-name drugs or 5% cost sharing in 2018. LIS beneficiaries pay less out of pocket than other beneficiaries. For example, full benefit dual eligibles pay no deductible, minimal cost sharing in the coverage gap, and no cost sharing above the catastrophic threshold. (See Table 7.)

Actual spending per beneficiary will vary depending on plan design (some enhanced plans provide additional subsidies in the coverage gap) and purchases of brand-name vs. generic drugs. After the catastrophic threshold has been reached, plans charge a beneficiary the greater of a nominal set co-payment for drugs or 5% coinsurance.\textsuperscript{71} Medicare subsidizes 80% of each plan’s costs for this catastrophic coverage.

CMS uses a set formula to update annual Part D coverage parameters including the standard deductible, the initial coverage limit, and beneficiary total out-of-pocket amounts.\textsuperscript{72} Annual percentage increases are based on average per-capita spending for covered outpatient drugs for Medicare beneficiaries during the 12-month period ending in July of the previous year.

**Actuarially Equivalent Plans**

Plan sponsors have a number of options when designing pricing and benefits. Insurers may offer basic plans that provide the same level of coverage as the Part D standard plan, but may modify certain parameters and cost sharing such as reducing the maximum $405 deductible, while also imposing cost-sharing requirements that are higher than 25%. For example, nearly all plans use a

\textsuperscript{70} Total reflects catastrophic limit of about $8,417.60 minus initial coverage limit of $3,750. Total spending per beneficiary will vary depending on plan design and purchases of brand-name vs. generic drugs. CMS thresholds are based on average spending data across all plans.

\textsuperscript{71} Nominal cost sharing is defined as the greater of (1) a co-payment of $3.35 in 2018 for a generic drug or preferred multiple source drug and $8.35 in 2018 for other drugs, or (2) 5% coinsurance.

\textsuperscript{72} Social Security Act, §1860D-2.
tiered cost-sharing structure, where beneficiaries have a lower co-payment for generic drugs, and higher cost sharing for more expensive brand-name drugs. (See “Tiered Formularies.”) In 2017, 41% of Part D enrollees in PDPs were in plans offering enhanced benefits, and 59% in plans that were actuarially equivalent to the standard benefit. No PDP enrollees were in defined standard benefit plans. 73

**Enhanced Plans**

Insurers may also offer enhanced coverage that exceeds the value of defined standard coverage. Enhanced coverage includes basic coverage and supplemental benefits such as reductions in cost sharing, including reductions in cost sharing in the coverage gap. A PDP sponsor may not offer an enhanced plan unless it also offers a standard or actuarially equivalent plan in the same region. The requirement is designed to ensure that Medicare beneficiaries have options for lower-cost plans.

The structure of the Part D program, including the large number of plans available in each region, can make it complicated for beneficiaries to compare plans. The ACA required CMS to streamline the number of Part D plans in each region and simplify the enrollment process. Since the 2011 plan year, CMS has required Part D sponsors that offer more than one plan per region to demonstrate meaningful differences between their plans, in terms of premiums, cost sharing, formulary design, or other benefits. 74 Plan sponsors may offer only one basic plan benefit design in a service area and no more than two enhanced alternative plans in each service area. Beginning in 2019, CMS will no longer require Part D sponsors offering two enhanced plans in a region to demonstrate meaningful differences between the enhanced plans. The sponsor still must demonstrate that the enhanced plans have meaningful differences from the basic plan, however. The change is designed to give Part D sponsors more flexibility in plan design. CMS will continue to limit Part D sponsors to offering no more than two enhanced plans in each region. 75

**The Coverage Gap**

One unique feature of the Medicare Part D drug benefit is the coverage gap—the period in which Part D enrollees are required to pay a larger share of total drug costs until they reach the catastrophic coverage level. Congress included the coverage gap in the benefit structure when the MMA was enacted in 2003 because the cost of continuous coverage would have exceeded goals for total spending.

As originally enacted, Part D provided a basic level of coverage for all beneficiaries, and extra protection for those with the highest drug costs (above the catastrophic limit). Part D enrollees who did not receive a low-income subsidy generally paid the full cost of drugs while in the coverage gap. (See original Part D in Figure 4.) The ACA, as amended, 76 included provisions to

---


76 Section 3301 of the ACA created the coverage gap manufacturer discount program. Section 1101 of the Health Care and Education Reconciliation Act of 2010 (P.L. 111-152 ) added the phase-in of government subsidies to close the...
gradually phase out the coverage gap by 2020, at which point beneficiaries in standard plans would have a 25% cost share from the time they meet a standard plan deductible until they reached the catastrophic threshold, after which cost sharing is reduced. (See “Phase Out of the Coverage Gap.”) Congress included provisions in BBA 2018 that phase out the Part D coverage gap for brand-name drugs in 2019, a year earlier than required by the ACA.\(^\text{77}\) (See “Phase Out of the Coverage Gap.”)

Beneficiaries may have different levels of actual out-of-pocket spending in the coverage gap depending on how their specific plans are structured and the percentage of brand-name and generic drugs that they use. Spending will also vary depending on whether a beneficiary qualifies for the LIS based on his or her income and assets. For example, dual-eligible beneficiaries who are institutionalized have zero co-payments for drugs listed on a plan formulary, including during the time they are in the coverage gap. Other LIS beneficiaries have set-dollar co-payments while they are in the coverage gap. In 2015, about 26% of Medicare Part D enrollees reached the coverage gap.\(^\text{78}\)

CMS offers enrollees suggestions for avoiding or delaying the coverage gap and for saving money while in the gap.\(^\text{79}\) Strategies for minimizing out-of-pocket spending include switching to generic,\(^\text{80}\) over-the-counter, mail-order, or other lower-cost drugs when possible; exploring national and community-based charitable programs or State Pharmacy Assistance Programs (SPAPs) that might offer assistance;\(^\text{81}\) and looking into Pharmaceutical Assistance Programs (also called Patient Assistance Programs or PAPs) offered by pharmaceutical manufacturers or independent charities.\(^\text{82}\) Additionally, CMS suggests that beneficiaries continue using their Medicare drug plan cards even when in the coverage gap. Using the cards helps to ensure that beneficiaries are charged the drug plan’s discounted, negotiated prices and that their out-of-pocket expenses count toward reaching the catastrophic coverage threshold.

**Phaseout of the Coverage Gap**

The ACA included provisions to gradually close the coverage gap by 2020 through a combination of manufacturer discounts and government subsidies. Under the ACA, pharmaceutical


\(^{79}\) Part D sponsors are required to ensure that their network pharmacies inform enrollees of any price differential between a covered drug and the lowest-price generic version of the drug that is therapeutically equivalent, bioequivalent, on the plan’s formulary, and available at that pharmacy.

\(^{80}\) Some states offer payment assistance for drug plan premiums and/or other drug costs for individuals who have trouble affording their medication but do not qualify for LIS. For example, a state may offer assistance to individuals with incomes between 150% and 300% of the FPL. To learn which states offer this assistance and for details on the state programs, see http://www.medicare.gov/pharmaceutical-assistance-program/state-programs.aspx.

\(^{81}\) Many major drug manufacturers offer assistance programs for the drugs they manufacture. Manufacturer patient assistance programs may be used outside the Part D benefit, and the value of benefits received under these programs does not count toward true out-of-pocket expenses. Independent charity patient assistance programs may provide assistance with Part D cost sharing, which does count toward true out-of-pocket expenses. To learn which manufacturers offer assistance, see http://www.medicare.gov/pharmaceutical-assistance-program/index.aspx. See also CRS Report R44264, Prescription Drug Discount Coupons and Patient Assistance Programs (PAPs).
manufacturers that want to participate in Medicare Part D must sign agreements to take part in the Medicare Coverage Gap Discount Program. The ACA required companies to provide a 50% discount on brand-name drugs for non-LIS Part D participants in the coverage gap. Drug makers began providing the brand-name drug discount in 2011. The ACA also gradually phased in additional federal subsidies for brand-name drugs purchased in the coverage gap, so that by 2020 a beneficiary would have 25% cost sharing in the coverage gap, Medicare would cover 25% of the cost of the drug, and the manufacturer discount would defray 50%. For generic drugs, the ACA phased in a 75% federal subsidy by 2020. The ACA did not impose a manufacturer discount on the less expensive generic drugs. (Those enrollees who reached the coverage gap in 2010 received a $250 discount, in the form of a check.) (See Table 5.)

BBA 2018 included provisions to close the coverage gap for brand-name drugs one year early, in 2019. (See Figure 3.) Beginning in 2019 and continuing forward, BBA 2018 (1) increases the manufacturer discount for brand-name drugs in the coverage gap to 70% from 50%; (2) expands the manufacturer discount to include biosimilar drugs, (3) sets the federal subsidy for brand-name drugs in the coverage gap at 5%, and (4) sets beneficiary cost sharing at 25%.

Figure 3. Closing the Doughnut Hole for Brand-Name Drugs in 2019

Source: CRS Graphic from CMS/BBA 2018 information.


84 Section 53116 of BBA 2018 increases the manufacturer discount to 70% beginning in 2019, while reducing the Medicare subsidy for brand-name drugs to 5% in the coverage gap. Enrollees will pay 25% of the negotiated price of brand-name drugs in the coverage gap, beginning in 2019. Beginning in 2019, Section 53113 of BBA 2018 expands the manufacturer discount to biosimilars, which are lower-cost versions of biologic drugs. Biologics and biosimilars are drugs produced from living organisms, rather than through a chemical process. The ACA originally excluded biosimilars from the manufacturer discount. In a separate 2018 rulemaking, CMS applied generic drug cost-sharing requirements to biosimilars purchased by LIS beneficiaries in all phases of the Part D benefit. The change will make biosimilars more affordable for LIS beneficiaries. See CMS, “Medicare Program: Contract Year 2019 Policy and Technical Changes to Medicare Advantage, Medicare Cost Plan, Medicare Fee-for-Service, Medicare Prescription Drug Benefit Programs, and PACE Program,” 83 Federal Register, April 16, 2018, p. 16610, at https://www.gpo.gov/fdsys/pkg/FR-2018-04-16/pdf/2018-07179.pdf.
Notes: The BBA 2018 closes the coverage gap for brand name drugs in 2019. BBA 2018 did not change the Medicare coverage gap discount for generic drugs, which will continue to be phased in through 2020.

BBA 2018 did not alter ACA requirements for generic drugs purchased in the coverage gap. For generic drugs, the coverage gap will close in 2020, as scheduled under the ACA. During plan year 2018, non-LIS enrollees pay 35% of the cost of brand-name drugs and 44% of the cost of generic drugs while in the coverage gap. Manufacturers provide a 50% discount for brand-name products, and the federal government subsidizes 15% of the cost of brand-name drugs and 56% of the cost of generics. In 2019, the federal government will subsidize 63% of the cost of generic drugs in the coverage gap, and enrollees will pay 37%.

### Table 5. Closing the Doughnut Hole
*(phase-in of subsidies and reduction in beneficiary cost sharing)*

<table>
<thead>
<tr>
<th></th>
<th>Brand Name Drugs</th>
<th>Generic Drugs</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Manufacturer</td>
<td>Medicare Subsidy</td>
</tr>
<tr>
<td>2011</td>
<td>50%</td>
<td>0</td>
</tr>
<tr>
<td>2012</td>
<td>50%</td>
<td>0</td>
</tr>
<tr>
<td>2013</td>
<td>50%</td>
<td>2.5%</td>
</tr>
<tr>
<td>2014</td>
<td>50%</td>
<td>2.5%</td>
</tr>
<tr>
<td>2015</td>
<td>50%</td>
<td>5%</td>
</tr>
<tr>
<td>2016</td>
<td>50%</td>
<td>5%</td>
</tr>
<tr>
<td>2017</td>
<td>50%</td>
<td>10%</td>
</tr>
<tr>
<td>2018</td>
<td>50%</td>
<td>15%</td>
</tr>
<tr>
<td>2019</td>
<td>70%</td>
<td>5%</td>
</tr>
<tr>
<td>2020</td>
<td>70%</td>
<td>5%</td>
</tr>
</tbody>
</table>

Source: CRS analysis of ACA, as amended by BBA 2018.

Notes: The federal government provides the generic drug subsidy.

In 2020, the coverage gap will be “closed” for both generic and brand-name drugs. (See Figure 4.) From 2020 onward, the federal government will subsidize 75% of the cost of generic drugs in the coverage gap and enrollees will pay 25%. Participants in enhanced Part D plans that provide extra assistance in the coverage gap receive the ACA required discounts and government subsidies for any remaining amounts owed, in addition to their enhanced plan benefits.\(^{85}\)

In 2016, more than 4.9 million beneficiaries who were in the coverage gap received the 50% manufacturer discount on brand-name drugs they purchased. Overall 2016 discounts totaled about $5.65 billion, with an average discount per beneficiary of $1,149.\(^{86}\)

---


**True Out-of-Pocket Costs**

Before catastrophic protection begins, Part D enrollees must incur a certain level of out-of-pocket costs. **True out-of-pocket costs** (TrOOP) are costs that are incurred by a beneficiary or are counted by CMS as incurred by a beneficiary, including a plan deductible, cost sharing up to the initial coverage limit, and the cost of certain drugs while in the doughnut hole, including the manufacturer subsidy.

Enrollee spending for Part D covered drugs is treated as a true out-of-pocket cost if it is: paid by the enrollee (including through a Medical Savings Account, Health Savings Account or Flexible Spending Account); paid by family members or friends; paid by a Qualified State Pharmacy Assistance Program; covered by a low-income subsidy; paid by most charities; covered by a drug manufacturer discount under the Medicare Coverage Gap Discount Program; covered by the Indian Health Service; or paid by an AIDS Drug Assistance Program.

Incurred costs do not include Part D premiums; costs for drugs that are not on the enrollee’s plan formulary; coverage by other insurance, including group health plans, workers’ compensation,

---

87 True out-of-pocket costs are the payments that count toward an enrollee’s Part D out-of-pocket threshold of $5,000 for 2018.


89 Added by §3314 of the ACA.

90 Added by §3314 of the ACA.
Part D plans’ supplemental or enhanced benefits, or other third parties; or Patient Assistance Programs operating outside of Part D. Additionally, while the manufacturer drug discounts count toward the TrOOP, federal subsidies for brand-name or generic drugs in the doughnut hole do not count.

### Examples of TrOOP Spending

Consider a non-LIS enrollee in a 2018 standard plan. In order to reach the initial coverage limit, the enrollee would need to incur TrOOP spending consisting of the $405 deductible and 25% coinsurance or co-payments on total drug spending up to $3,750 ($836.25+$405=$1,214.25). The beneficiary now faces about $3,758.75 of additional spending in the doughnut hole before he or she reaches the catastrophic threshold (a total of $5,000 in out-of-pocket spending).

While in the coverage gap in 2018, a beneficiary pays 35% of the cost of brand-name drugs, including any pharmacy dispensing fees. The manufacturer provides a 50% discount on the negotiated price of brand-name drugs, which will count toward TrOOP. The federal government provides a subsidy of 15% of the cost of the brand-name drug, which will not count toward TrOOP.

A beneficiary who purchases generic drugs in the coverage gap in 2018 pays 44% of the cost of drugs, including pharmacy dispensing fees, which will be counted toward TrOOP. The federal government provides a 56% coverage subsidy that will not count toward TrOOP.

In one example, the beneficiary buys a brand-name drug that has a negotiated price of $60 and a $2 pharmacy dispensing fee. The total cost is $62. The beneficiary will pay 35% of the cost of the drug and dispensing fee ($62 × 0.35 = $21.70). The manufacturer discount reduces the price of the drug by $30 (50% of the $60 negotiated price.) In this case, TrOOP will be $51.70 (The $21.70 beneficiary price, including a portion of the dispensing fee, plus the $30 manufacturer discount). The remaining $10.30 does not count toward TrOOP.

In another example, the beneficiary buys a generic drug. The price for the generic drug is $20 and the dispensing fee is $2. The beneficiary will pay 44% of the cost of the generic drug plus the pharmacy fee ($22 × 0.44 = $9.68). The $9.68 will count as TrOOP. The government’s 56% coverage portion ($12.32) will not count as TrOOP.

In 2015, 3.6 million Part D enrollees (about 9%) exceeded the out-of-pocket threshold and reached the catastrophic phase of the benefit. These enrollees accounted for about 65% of gross Part D spending on basic benefits that year. Medicare picks up a larger share of spending (reinsurance) for individuals who reach the catastrophic threshold. Spending for reinsurance is now the largest share of spending for the Part D program. Of those reaching the catastrophic phase in 2015, around 2.6 million received the low-income subsidy. However, in recent years the number of non-LIS enrollees reaching the coverage gap has been growing more rapidly. This growth is due to several factors including higher prices for certain Part-D covered drugs, ACA provisions that allow enrollees to count the manufacturer discount on brand-name drugs toward TrOOP, and higher enrollment growth by non-LIS enrollees compared to LIS enrollees over that time.

---

91 For brand-name drugs, any pharmacy dispensing fees are added to the price of the drug after the manufacturer’s discount has been applied, and the full amount of the fee counts as TrOOP. For generic drugs, dispensing fees are counted as part of the cost of the drug before the government subsidy is applied. Therefore, only a percentage of the dispensing fee, not the full amount, is counted in TrOOP.


94 Ibid, p. 423.
Low-Income Subsidies

Medicare Part D provides subsidies to assist low-income beneficiaries with premiums and cost sharing.\(^5\) LIS cost sharing is linked to the standard prescription drug coverage and varies according to a beneficiary’s assets and income and, also, whether a beneficiary is institutionalized, or is receiving community-based care. Full-subsidy eligibles\(^6\) have no deductible, minimal cost sharing during the initial coverage period and coverage gap, and no cost sharing above the catastrophic threshold. Additionally, full-benefit dual eligibles who are residents of medical institutions or nursing facilities have no cost sharing. (See “Eligibility for Low-Income Assistance.”)

Premium Assistance

Full-Subsidy-Eligible Individuals

Low-income beneficiaries who qualify for a full subsidy do not pay monthly plan premiums if they enroll in certain, lower-cost Part D plans. A PDP qualifies as a lower-cost or “benchmark” plan if it offers basic Part D coverage and charges premiums equal to, or below, a regional low-income premium subsidy amount calculated by CMS each year. (See “Availability of Low-Income Plans.”) If a LIS beneficiary selects a plan with a premium that is higher than the regional benchmark, he or she must pay the extra cost.

Partial-Subsidy-Eligible Individuals

Partial-subsidy-eligible individuals receive premium assistance based on an income sliding scale, as specified in Table 6.

<table>
<thead>
<tr>
<th>Federal Poverty Level (FPL) and Asset Thresholds</th>
<th>Percentage of Premium Subsidy Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Income up to or at 135% FPL; assets that do not exceed the calendar year resource limits for individuals or couples.</td>
<td>100%</td>
</tr>
<tr>
<td>Income above 135% FPL but at or below 140% FPL; assets that do not exceed the calendar year resource limits for individuals or couples.</td>
<td>75%</td>
</tr>
<tr>
<td>Income above 140% FPL but at or below 145% FPL; assets that do not exceed the calendar year resource limits for individuals or couples.</td>
<td>50%</td>
</tr>
<tr>
<td>Income above 145% FPL but below 150% FPL; assets that do not exceed the calendar year resource limits for individuals or couples.</td>
<td>25%</td>
</tr>
</tbody>
</table>


\(^5\) While assistance with Part B premiums and cost sharing for low-income beneficiaries is primarily paid for by state Medicaid programs (through their Medicare Savings Programs), the Part D low-income subsidy is federally funded.

Cost-Sharing Subsidies

Cost-sharing subsidies for LIS enrollees are linked to standard prescription drug coverage. Full-subsidy eligibles have no deductible, minimal cost sharing during the initial coverage period and coverage gap, and no cost sharing above the catastrophic threshold. Partial-subsidy individuals have higher cost sharing. (See Table 7.)

Other specific policies for dual eligibles include the following:

- Full-benefit, dual eligibles who are residents of medical institutions or nursing facilities have no cost sharing, with some exceptions.97 The ACA expanded the LIS subsidy so that beneficiaries receiving home and community-based services in lieu of institutional care also have no cost sharing.

- Other full-benefit, dual-eligible individuals with incomes up to or at 100% of FPL pay $1.25 for a generic drug prescription or preferred multiple-source drug prescription and $3.70 for any other drug prescription in 2018 up to the catastrophic threshold. They have no co-payments above the catastrophic limit.

- Full-subsidy-eligible individuals with incomes above 100% of FPL have cost sharing for all drug costs, up to the catastrophic limit of $3.35 in 2018 for a generic drug or preferred multiple-source drug and $8.35 for any other drug.

- Partial-subsidy-eligible individuals have an $83 deductible in 2018, 15% coinsurance for all costs up to the catastrophic trigger, and cost sharing above this level of $3.35 for a generic drug prescription or preferred multiple source drug prescription and $8.35 for any other drug prescription.

Each year, cost-sharing amounts for full-benefit dual eligibles up to or at 100% of FPL are updated by the annual percentage increase in the Consumer Price Index (CPI). The cost-sharing amounts for all other beneficiaries, and the deductible amount for other subsidy-eligible individuals, are increased by the annual percentage increase in per-capita beneficiary expenditures for Part D-covered drugs.

Table 7. Part D Standard Benefits, 2018
(by per capita drug spending category)

<table>
<thead>
<tr>
<th>Total drug Spending (Dollar Ranges)</th>
<th>Non-LIS Beneficiaries</th>
<th>Low-Income Subsidy (LIS)-Eligible Individuals</th>
<th>Other Subsidy Eligible</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Paid by Part D</td>
<td>Paid by Enrollee</td>
<td>Paid by Part D</td>
</tr>
<tr>
<td>$0 up to $405 Deductible</td>
<td>0%</td>
<td>$405</td>
<td>$405</td>
</tr>
<tr>
<td>Between Deductible and Initial Coverage Limit ($405.01-$3,750)</td>
<td>75%</td>
<td>25%</td>
<td>100% less enrollee cost sharing</td>
</tr>
<tr>
<td>Coverage Gap</td>
<td>5% (plus 50% manufacturer discount) for brand name drugs and 56% for generic drugs</td>
<td>35% for brand name drugs and 44% for generic drugs</td>
<td>100% less enrollee cost sharing</td>
</tr>
<tr>
<td>Over Catastrophic Threshold</td>
<td>95%</td>
<td>5%</td>
<td>100%</td>
</tr>
</tbody>
</table>


a. Maximum of $1.25 per prescription for generic or preferred drugs that are multiple source drugs; $3.70 per prescription for other drugs.

b. Maximum of $3.35 per prescription for generic or preferred drugs that are multiple source drugs; $8.35 per prescription for other drugs.

c. Minimum of $3.35 per prescription for generic or preferred drugs that are multiple source drugs; $8.35 per prescription for other drugs.

**Employer Subsidies**

The MMA included provisions designed to encourage employers to continue to offer drug benefits to their Medicare-eligible retirees. Employers have a number of options for providing such coverage.
Retiree Drug Subsidy

Employers and union groups that provide prescription drug insurance to Medicare-eligible, retired workers may apply for federal retiree drug subsidies (RDS). To qualify, an employer or union must offer drug benefits that are actuarially equivalent to, or more generous than, standard Part D prescription drug coverage. Sponsors must submit applications for CMS approval at least 90 days prior to the beginning of a plan year.

Medicare provides payments for eligible retirees, defined as individuals who are entitled to Medicare benefits under Part A and/or are enrolled in Part B, and who live in the service area of a Part D plan. An individual must be a retired participant in an employer- or union-qualified group health plan or the Medicare-enrolled spouse or dependent of a retired participant. A retiree health plan cannot receive a subsidy for a current worker or an individual who is enrolled in a Part D plan. (An employer or union does have the option of sponsoring its own Part D plan.)

For each retiree enrolled in a qualified plan in 2018, sponsors receive a federal subsidy equal to 28% of gross prescription drug costs between a threshold of $405 and a cost limit of $8,350. The retiree subsidies are designed to encourage employers to maintain drug coverage, and have generally been less expensive for Medicare than enrolling these beneficiaries in a Part D drug plan. In 2018, the average annual RDS is forecast to be about $531 per beneficiary compared to average per beneficiary costs of $2,120 for Part D beneficiaries.

Prior to enactment of the ACA, group health plans offering qualified drug coverage were eligible to receive the Medicare retiree health subsidy and, in addition, claim a federal tax deduction for the subsidy, along with the rest of the plan’s spending on retiree health benefits. The ACA prohibited companies, beginning in 2013, from claiming a tax deduction for the Medicare drug subsidy. In addition, retiree health plans are not eligible for ACA manufacturer discounts on brand-name drugs through the coverage gap discount program. These changes, which result in higher relative costs for retiree plans, are prompting employers to move away from the retiree drug subsidy program. The Medicare Trustees predict that the share of beneficiaries covered through the retiree drug subsidy will decline from about 20% of Part D enrollment in 2010 to about 2% in 2027.

Employer Group Waiver Plans

As fewer employers and unions utilize the Part D retiree drug subsidy, a growing number are providing retirees drug benefits through special Part D employer group waiver plans (EGWPs). Under an EGWP, a union or employer provides Part D coverage to its Medicare-eligible retirees and their eligible spouses and dependents. A union or employer may contract with a pharmacy

---

benefits manager (PBM) or insurer that is a Part D sponsor to provide the Part D EGWP or become a direct Part D plan sponsor.\footnote{CMS, Medicare Prescription Drug Benefit Manual, Chapter 12, “Employer/Union Sponsored Group Health Plans,” Rev. November 7, 2008, at http://www.cms.gov/Regulations-and-Guidance/Guidance/Transmittals/Downloads/R6PDB.pdf. Pharmacy benefit managers are middlemen that negotiate drug prices, set plan formularies, create plan pharmacy networks and perform other related functions for health insurers.} Employers and unions may provide supplemental benefits that wrap around an EGWP, such as prescription drugs that are not on the Part D formulary. CMS allows waivers of certain Part D requirements for EGWPs. There are some differences in reimbursement for EGWPs and other Part D plans. The Medicare Trustees forecast that the share of individuals enrolled in EGWPs will rise from about 6% of all Part D enrollees in 2007 to about 15% in 2018.\footnote{2017 and 2018 Medicare Trustees Report, Table IV.B7, p. 141, at https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/ReportsTrustFunds/Downloads/TR2018.pdf. Employers may also enroll Part D eligible retirees in individual PDPs.}

\section*{Drug Coverage}

In order for a drug to be paid by Medicare’s prescription drug benefit, it must be a drug that is covered under Part D and included in the formulary of an individual’s Part D plan. (See “Formularies.”) The MMA defines covered Part D drugs as (1) outpatient prescription drugs approved by the Food and Drug Administration (FDA), and used for a medically accepted indication; (2) biological products that may be dispensed only upon a prescription and that are licensed under the Public Health Service (PHS) Act and produced at a licensed establishment; (3) insulin (including medical supplies associated with the injection of insulin); and (4) vaccines licensed under the PHS Act. Drugs can also be treated as part of a plan’s formulary as the result of a beneficiary coverage determination or appeal.

Certain drugs are excluded from Part D coverage by law, including drugs specifically excluded from coverage under Medicaid. The exclusion applies to (1) drugs used for anorexia, weight loss, or weight gain; (2) fertility drugs; (3) drugs used for cosmetic purposes or hair growth; (4) drugs for symptomatic relief for coughs and colds; (5) prescription vitamins and minerals; and (6) covered drugs when the manufacturer requires, as a condition of sale, that associated tests be purchased exclusively from the manufacturer. Drugs used for the treatment of sexual or erectile dysfunction are excluded from coverage unless they are used to treat another condition for which the drug has been approved by the FDA.\footnote{These changes were required by Section 175 of the Medicare Improvements for Patients and Providers Act (MIPPA; P.L. 110-275).}

Some previously barred drugs are now covered. Since January 1, 2013, Part D plans have been required to include benzodiazepines in their formularies.\footnote{CMS, Medicare Prescription Drug Benefit Manual, Chapter 6, “Part D Drugs and Formulary Requirements,” Section 20.1, Rev. January 15, 2016, at https://www.cms.gov/Medicare/Prescription-Drug-Coverage/PrescriptionDrugCovContra/Downloads/Part-D-Benefits-Manual-Chapter-6.pdf.} Barbiturates must be included in plan formularies for an indication of epilepsy, cancer, or chronic mental health disorders. Effective in January 2014, the ACA removed smoking cessation agents, barbiturates and benzodiazepines from the list of drugs allowed to be excluded from Medicaid coverage. The ACA provisions meant that Part D restrictions on barbiturate coverage (i.e., limiting the drugs to treatment of epilepsy, cancer, or chronic mental health disorders) were ended.\footnote{CMS, “Announcement of Calendar Year (CY) 2014 Medicare Advantage Capitation Rates and Medicare Advantage Payments to Medicare Advantage Organizations,” December 17, 2013, at https://www.cms.gov/Medicare/Prescription-Drug-Coverage/PrescriptionDrugCovContra/Downloads/Announcement_CY2014_.pdf. Employers may also enroll Part D eligible retirees in individual PDPs.}

\begin{footnotesize}
\footnotetext[106]{These changes were required by Section 175 of the Medicare Improvements for Patients and Providers Act (MIPPA; P.L. 110-275).}
\end{footnotesize}
If a state covers excluded drugs for Medicaid beneficiaries, it must also cover them for dual eligibles in cases where the drugs are determined to be medically necessary. Dual eligibles may therefore receive coverage from Medicaid for some drugs that are excluded from Medicare. Additionally, a Part D sponsor may elect to include one or more of these drugs in an enhanced Part D plan; however, no federal subsidy is available for the associated costs.

**Drugs Covered by Other Parts of Medicare**

Part D drug plans are prohibited from covering drugs covered by other parts of Medicare. This includes prescription medications provided during a stay in a hospital or skilled nursing facility that are paid for by the Part A program, and the limited circumstances when Part B covers prescription drugs. Part B-covered drugs include drugs that are not usually self-administered and are provided incidental to a physician’s professional services or drugs necessary for the proper functioning of Part B durable medical equipment. These include such things as immunosuppressive drugs for persons who have had a Medicare-covered transplant; erythropoietin (an anti-anemia drug) for persons with end-stage renal disease; oral anti-cancer drugs; drugs requiring administration via a nebulizer or infusion pump in the home; and certain vaccines (influenza, pneumococcal, and hepatitis B for intermediate- or high-risk persons).  

**Formularies**

Prescription drug plans operate formularies, which are lists of drugs that a plan chooses to cover and the terms under which they are covered. This means that plans can choose to cover some, but not all, FDA-approved prescription drugs.

A Part D sponsor’s formulary must be developed and reviewed by a special CMS-approved Pharmacy and Therapeutics Committee. A majority of the committee members must be practicing physicians or practicing pharmacists and the committees must each include one physician and one pharmacist who are experts in caring for elderly or disabled individuals. Committees are to base decisions on the strength of scientific evidence and standards of practice when developing and reviewing formularies. According to CMS, the committees should also take into account whether including a particular drug in a formulary (or in a particular tier of drugs) has therapeutic value in terms of safety and efficacy. The committees review prior authorization, step therapy, and other methods of limiting or managing access to drugs by Part D plan enrollees. (See “Drug Utilization.”)

---


Formulary Categories and Classes

Formulary drugs are grouped into categories and classes of products that work in a similar way or are used to treat the same condition. The MMA required CMS to ask the United States Pharmacopeial Convention (USP)\(^{110}\) to develop a list of categories and classes for plans and to periodically revise such classifications. A plan formulary must include at least two drugs in each category or class used to treat the same medical condition (unless only one drug is available in the category or class, or two drugs are available but one drug is clinically superior). The two-drug requirement must be met by providing two chemically distinct drugs. (Plans cannot meet the requirement by including two dosage forms or strengths of the same drug or a brand-name drug and its generic equivalent.)

Six Classes of Clinical Concern

In general, Part D drug plans are required to operate formularies that cover at least two drugs in each drug class. However, under CMS guidelines, Part D plans have been required to cover substantially all available drugs in the following six categories: immunosuppressant, antidepressant, antipsychotic, anticonvulsant, antiretroviral, and antineoplastic.\(^{111}\) Plan sponsors have not been allowed to steer beneficiaries who are already using these drugs toward alternative therapies via policies such as requiring prior authorization or step-therapy mandates (see “Drug Utilization”).\(^{112}\) This policy was designed to mitigate the risk that drug therapy could be interrupted for vulnerable populations.

The Medicare Improvements for Patients and Providers Act of 2008 (MIPPA; P.L. 110-275) and the ACA both codified the general policy of creating protected classes, while directing the Secretary of Health and Human Services (HHS) to spell out more specific criteria for identifying drug categories or classes of clinical concern.\(^{113}\) As part of this process, the statutes allow HHS to revamp the current protected classes and categories, including permitting Part D sponsors to exclude certain drugs from their formularies (or limit access to such drugs through utilization management or prior authorization restrictions).\(^{114}\)

\(^{110}\) The United States Pharmacopeial Convention (USP) is a nonprofit organization that sets standards for the identity, strength, quality, and purity of medicines, food ingredients and dietary supplements.


\(^{112}\) For beneficiaries beginning treatment in these categories, such management techniques may be used for categories other than HIV/AIDS drugs.

\(^{113}\) The MIPPA required that, beginning with plan year 2010, the HHS Secretary identify categories and classes of drugs for which both of the following criteria are met: 1) restricted access to drugs in the category or class would have major or life threatening clinical consequences for individuals who have a disease or disorder treated by the drugs in such category or class and 2) there is significant clinical need for such individuals to have access to multiple drugs within a category or class due to unique chemical actions and pharmacological effects of the drugs within the category or class. The ACA specified that the six drug categories or classes of clinical concern would remain in place until the HHS Secretary established new criteria to identify drug categories or classes of clinical concern under §1860D–4(b)(3)(G) of the Social Security Act through notice and rulemaking.

\(^{114}\) In January 2014, CMS issued proposed rules that would have narrowed the protected classes to anticonvulsants, antiretrovirals, and antineoplastics, beginning in plan year 2015. Antipsychotic drugs would have continued to be treated as a class of clinical concern in 2015 and until CMS determined that it was appropriate to change the criteria for these products. In May 2014, CMS announced it would not finalize the proposed regulations relating to the six protected classes. See CMS, “Medicare Program; Contract Year 2015 Policy and Technical Changes to the Medicare Advantage and the Medicare Prescription Drug Benefit Programs; Proposed Rule,” 79 Federal Register, pp. 1936 and
Vaccines

The Tax Relief and Health Care Act of 2006 (P.L. 109-432) required that Medicare drug plans, beginning in 2008, include all commercially available vaccines in their drug formularies, with the exception of vaccines covered under Medicare Part B. Medicare Part B generally covers vaccinations for influenza, pneumonia, and the Hepatitis B vaccine for intermediate to high-risk cases. Part B will also cover immunizations for patients exposed to an injury or disease, such as tetanus shots. The Tax Relief and Health Care Act of 2006 modified the definition of a Part D drug to require plans to cover the costs for administering Part D-covered vaccines, as well as the vaccine itself. CMS considers the negotiated price for a Part D vaccine to include the vaccine ingredient cost, a dispensing fee (if applicable), sales tax (if applicable) and a vaccine administration fee.

CMS policy is that Part D vaccines, including administration costs, are to be billed on one claim. The policy applies to providers both in- and out-of-network. Unlike Part B vaccines, which are billed directly to Medicare, Part D claims are paid by the insurance provider; therefore the Part D entity/individual administering the vaccine may not be able to directly bill the Part D sponsor for the vaccine and administration. In some instances, patients must pay a physician for a vaccination up front, and then submit the bill to their insurance plan. CMS has issued guidance to plans regarding alternative billing options, such as allowing in-network pharmacists to administer vaccinations and to directly bill Part D, or having physicians electronically submit claims to Part D plans.

Plan-Year Formulary Changes

Part D plans may alter their formularies from year to year. Plans are also allowed, in limited circumstances, to make changes to their formularies within a plan year. Plans generally may not change therapeutic categories and classes of drugs within a plan year, except to account for new therapeutic uses or to add newly approved Part D drugs. If Part D plans remove drugs from their formularies during a plan year (or change cost-sharing or access requirements), they must provide timely notice to CMS, affected enrollees, physicians, pharmacies, and pharmacists.

Starting in CY2019, Part D sponsors may immediately remove brand-name drugs from a formulary (or change the cost-sharing tier) during a plan year if they replace the brand-name product with a therapeutically equivalent generic that is placed on the same or lower cost-sharing tier and if the generic is subject to the same or less restrictive utilization criteria than the brand-name drug. To qualify for substitution, the new generic must have been released to the market after the initial formulary was submitted. Plans are not required to give prior notice of the formulary change but (1) must generally advise enrollees in plan documents, such as annual reports.

Other formulary changes may be made in the following circumstances:

- Plans may immediately remove drugs from their formularies that are deemed unsafe by the FDA or are pulled from the market by their manufacturers. Plans do not have to provide prior notice of such actions, but must provide retrospective notice to CMS and other affected parties.
- After March 1 each year, Part D sponsors may make maintenance changes to their formulary, such as replacing brand name with new generic drugs or modifying formularies as a result of new information on drug safety or effectiveness.

**Transition Policies**

CMS established transition standards to ensure that enrollees who move to a new plan do not abruptly lose coverage for drugs used in ongoing therapy—for example, in a case where a new plan does not cover a drug a beneficiary has been using. Transition policies also cover cases where enrollees are affected by formulary changes in their current plan from one year to the next.\footnote{Ibid. In most cases, plans may not remove covered Part D drugs from their formularies, or make any change in preferred or tiered cost-sharing status of a covered Part D drug, between the beginning of the annual coordinated election period October 15, and 60 days after the beginning of the contract year. For example, if a plan sponsor alters an announced formulary to account for a new drug or therapeutic use. According to CMS, a minimum of a 108-day look-back (consistent with other reviews) is typically needed to document ongoing drug therapy.} In such cases, a beneficiary can request that his or her physician check to see if the prescription can be switched to a similar drug on the new formulary. If the physician determines that a specific drug is medically necessary, the doctor may request that the plan make an exception to its policy.

Plans are required to continue a beneficiary’s previous prescription during the first 90 days of the calendar year. Any refill must be for an approved month’s supply (unless the prescription is written for a shorter period) for any drug not on the plan’s formulary.\footnote{Ibid. In most cases, plans may not remove covered Part D drugs from their formularies, or make any change in preferred or tiered cost-sharing status of a covered Part D drug, between the beginning of the annual coordinated election period October 15, and 60 days after the beginning of the contract year. For example, if a plan sponsor alters an announced formulary to account for a new drug or therapeutic use. According to CMS, a minimum of a 108-day look-back (consistent with other reviews) is typically needed to document ongoing drug therapy.} The requirement also applies to drugs that are on a plan’s formulary, but which require prior authorization or step therapy. Transition policies also cover situations where enrollees undergo changes in the level of care, such as moving from a hospital to home.

---


\footnote{CMS, “Medicare Program: Contract Year 2019 Policy and Technical Changes to Medicare Advantage, Medicare Cost Plan, Medicare Fee-for-Service, Medicare Prescription Drug Benefit Programs, and PACE Program,” 83 Federal Register, April 16, 2018, p. 16604, at https://www.gpo.gov/fdsys/pkg/FR-2018-04-16/pdf/2018-07179.pdf. See also 42 C.F.R. § 423.120. The rule changed the transition requirement to an approved month’s supply (from a 30-day supply) so that it will be equivalent to the approved month’s supply measurement in the applicable plan’s annual bid to provide Part D services. The rule also shorted the length of transition prescriptions that are provided to residents of long-term care facilities to an approved month’s supply.}
Drug Utilization Management Programs

CMS regulations require that each Part D plan have an appropriate drug utilization management program that (1) includes incentives to reduce costs when medically appropriate, and (2) maintains policies and systems to assist in preventing over-utilization and under-utilization of prescribed medications. Since the Part D program began in 2006, the trend among plans has been to impose greater cost-sharing and utilization management. In addition, during the past several years, CMS has imposed more stringent requirements on plans in an effort to identify possible program fraud and abuse involving certain prescription drugs.

Tiered Formularies

Plan D plan sponsors may assign formulary drugs to tiers that correspond to different levels of cost sharing. In general, this structured pricing encourages use of generic medications by placing these medicines on the plan tier with the lowest out-of-pocket costs, and discourages the use of more expensive drugs by putting them on tiers that require higher out-of-pocket spending. Plans have flexibility in structuring the tiers. Different plans may place the same drug on different tiers, and drugs in parallel tiers may not have the same cost-sharing requirements. To illustrate, a five-tiered formulary may be structured so that Tier 1 includes preferred generics, Tier 2 includes non-preferred generics, Tier 3 contains preferred brand-name drugs, Tier 4 includes higher-cost, non-preferred brand names, and Tier 5 (the “specialty tier”) has very expensive or rare drugs.

In 2018, almost all PDPs had five cost-sharing tiers, though co-payments and coinsurance varied among plans.

Part D plans are permitted to institute a specialty tier for expensive products (e.g., unique drugs or biologics). Beneficiaries cannot appeal cost-sharing amounts for drugs placed on a specialty tier. Plans typically charge a percentage of the cost of a drug on the specialty tier (coinsurance), rather than a flat co-payment. To ensure that beneficiaries dependent on specialty drugs are not “unduly discouraged” from enrolling in tiered plans, CMS has instituted the following conditions: (1) a plan may have only one specialty tier; (2) a plan with a standard deductible may impose coinsurance of up to 25% for specialty drugs, while a plan with a reduced or zero deductible may impose coinsurance of up to 33%, and (3) only drugs with negotiated prices exceeding a set threshold may be placed on a specialty tier ($670 for a month’s supply for 2018). Although Part D specialty drugs account for less than 1% of Part D prescriptions, they account for nearly 20% of Part D expenditures.

The specialty tier is not necessarily the tier with the highest coinsurance. Some Part D plans charge coinsurance greater than 33% for drugs on a non-preferred brand name formulary tier, up to the initial coverage limit. According to CMS, best practices for developing formularies dictate

---

124 Each plan negotiates the price of each drug with its manufacturer. If a plan obtains a significant rebate on one brand-name drug, but not on a competing drug used in treating the same condition, the plan may charge a lower co-payment for the former (preferred) drug and a higher co-payment for the latter (non-preferred).
that drugs are placed in a non-preferred tier only when drugs that are therapeutically similar (i.e., drugs that provide similar treatment outcomes) are in more preferable positions on the formulary.\textsuperscript{127} CMS reviews plan sponsors’ drug tier placement to ensure their formulary does not substantially discourage enrollment of certain beneficiaries, such as those with potentially high drug costs.

Other Drug Utilization Controls

Other utilization restrictions include (1) prior authorization, in which a beneficiary, with assistance of a prescribing physician, must obtain a plan’s approval before it will cover a particular drug; (2) step therapy, where a beneficiary must first try a generic or less expensive drug to see if it works as well as the one prescribed; and (3) quantity limits, where the supply of drugs is initially limited to reduce the likelihood of waste (e.g., if a drug was not effective for a beneficiary or had intolerable side effects). A beneficiary who wants his or her plan to waive a utilization control must provide a physician statement indicating that a prescribed drug and dosage is medically necessary and providing a rationale as to why restrictions are not appropriate.

Since 2014, PDPs have been required to apply a daily cost-sharing rate to prescriptions for less than a 30-day supply of medication (with some exceptions).\textsuperscript{128} The daily cost-sharing rate is defined as the monthly co-payment under the enrollee’s Part D plan, divided by 30 or 31 and rounded to the nearest lower dollar amount. The daily cost-sharing requirement gives beneficiaries an incentive to ask physicians for shorter prescriptions when trying a medication for the first time because the Part D sponsor will charge the lower, pro-rated cost sharing when the prescription is dispensed. Shorter prescriptions are seen as a means to reduce Part D beneficiary costs and drug waste in cases where a prescribed drug is ultimately found not to be effective.\textsuperscript{129}

Part D Opioid Overutilization Monitoring

Since 2013, CMS has operated a two-part system to combat inappropriate utilization of opioids in Part D. First, CMS has encouraged Part D plans to enhance their internal formulary and drug utilization review programs to provide opioid safety controls at the point of sale, retrospectively review drug claims to identify beneficiaries at risk of overutilization, and perform case management for beneficiaries deemed at risk of opioid abuse.\textsuperscript{130} Second, CMS has operated a program-wide Overutilization Monitoring System (OMS) to verify that Part D sponsors have established effective and appropriate opioid management programs. Under the OMS, CMS performs its own retrospective reviews of Part D prescription data to identify enrollees at risk of opioid overutilization. CMS defines at-risk beneficiaries as those using high dosages of opioids


\textsuperscript{128} 42 C.F.R. §423.153(b)(4)(i).


(over a specified period of time) provided by multiple prescribers or pharmacies.\textsuperscript{131} Part D plans are to review drug use of beneficiaries identified through the OMS.

The Comprehensive Addiction and Recovery Act of 2016 (CARA; P.L. 114-198) provides Part D sponsors with authority to limit the number of pharmacies and prescribers that can be used by enrollees identified as at-risk of overutilization of frequently abused drugs, beginning in 2019. This “lock-in” provision is designed to reduce fraud and abuse by making it easier to control enrollee opioid use.

In April 2018, CMS issued final rules to implement the CARA provisions. The rules use OMS clinical guidelines as the basis for determining whether a Part D beneficiary is at-risk for opioid overutilization.\textsuperscript{132} Beginning in 2019, Part D plan sponsors will be allowed to limit an at-risk beneficiary’s access to frequently abused drugs (defined by CMS as opioids and benzodiazepines) by imposing a prescription safety edit at the point of sale, and/or by requiring an at-risk enrollee to obtain opioids only from select pharmacy(ies) and/or prescriber(s), after case management and appropriate notice.\textsuperscript{133} The rules limit the use of SEPs by low-income beneficiaries deemed at-risk or potentially at-risk for prescription drug abuse.\textsuperscript{134} The OMS and lock-in policies will not apply to Part D beneficiaries being treated for active cancer-related pain, receiving palliative or end-of-life care, or in long-term care for drug management programs.

In addition, the final rule seeks to reduce opioid fraud and abuse by barring Part D plans from covering prescriptions written by physicians or other health care providers who are on a special CMS preclusion list.\textsuperscript{135} The preclusion list requirement will be in addition to CMS’s existing authority to revoke Medicare enrollment for physicians or other professionals determined to have a prescribing pattern that is “abusive, represents a threat to the health and safety of Medicare beneficiaries, or otherwise fails to meet Medicare requirements.” CMS also may revoke Medicare enrollment if a prescriber’s Drug Enforcement Administration (DEA) Certificate of Registration is suspended or revoked, or if his or her ability to prescribe drugs is revoked by any state in which he or she practices.\textsuperscript{136}

\begin{itemize}
  \item \textsuperscript{132} CMS, “Medicare Program; Contract Year 2019 Policy and Technical Changes to the Medicare Advantage, Medicare Cost Plan, Medicare Fee-for-Service, the Medicare Prescription Drug Benefit Programs, and the PACE Program,” 83 Federal Register, April 16, 2018, pp. 16442-16480.
  \item \textsuperscript{133} Ibid. An enrollee may ask for a redetermination of a designation as an at-risk beneficiary.
  \item \textsuperscript{134} Ibid.
  \item \textsuperscript{135} Ibid. The preclusion list covers prescribers, individuals, and entities that (a) are revoked from Medicare, are under an active reenrollment bar, and for whom CMS determines that the underlying conduct that led to the revocation is detrimental to the best interests of the Medicare program; or (b) have engaged in behavior for which CMS could have revoked the prescriber, individual, or entity to the extent applicable if they had been enrolled in Medicare, and CMS determines that the underlying conduct that would have led to the revocation is detrimental to the best interests of the Medicare program.
\end{itemize}
Medication Therapy Management

Part D plans (with some exceptions) must include a Medication Therapy Management (MTM) program, which is a system of coordinated pharmacy care for patients with multiple medical conditions who may be seeing a series of practitioners. A MTM program includes medication reviews, patient consultation and education and other services. Each plan’s program must be reviewed and approved annually by CMS, and is one of several, required elements that is considered when CMS evaluates a sponsor’s bid to participate in the Part D program for an upcoming contract year.

Part D sponsors must automatically enroll beneficiaries in a MTM program if they meet the following criteria: (1) they have multiple chronic diseases, with three being the maximum that can be required; (2) they are taking at least two to eight Part D drugs; and (3) they are likely to have annual covered drug costs that exceed $3,967 in 2018.137

Part D sponsors also may target beneficiaries with any chronic diseases or with specific chronic diseases. If plans target beneficiaries with specific diseases, they must include at least five of the diseases CMS has defined as nine core chronic conditions:138

- Alzheimer’s Disease;
- Chronic Heart Failure;
- Diabetes;
- Dyslipidemia;
- End-Stage Renal Disease (ESRD);
- Hypertension;
- Respiratory Disease (such as asthma or chronic lung disorders);
- Bone Disease-Arthritis; and
- Mental Health (such as depression, schizophrenia, or bipolar disorder).

CMS guidelines state that, once enrolled, beneficiaries should remain in a MTM program for the course of a plan year, even if they no longer meet one or more of the eligibility criteria. The MTM program must include a comprehensive review of a beneficiary’s medications, intervention with both beneficiaries and prescribers, and quarterly, targeted medication reviews.139 In 2015, CMS announced a five-year MTM pilot program, beginning in 2017, to test whether offering Part D sponsors additional payment incentives and more regulatory flexibility will lead to improved outcomes for MTM beneficiaries.140 CMS says 11 states are eligible to participate in the program.

Part D Plans: Payment and Participation

Medicare Part D participants must obtain coverage through a private insurer, or other entity, that contracts with Medicare (a plan sponsor). As previously described, beneficiaries may select either

138 Ibid.
139 Ibid.
a stand-alone prescription drug plan or a Medicare Advantage plan that includes prescription drug coverage along with other Medicare services.\(^{141}\)

PDPs are required to be available, region-wide within each of the 34 designated PDP regions. MA-PDs are generally local, operating on a countywide basis; however, region-wide MA-PDs are available in many of the 26 MA regions in the United States. A PDP sponsor may offer a PDP in more than one region, including all PDP regions; however, the sponsor must submit separate coverage bids for each region it serves.\(^{142}\) Medicare payments to plans are determined through a competitive bidding process, and enrollee premiums are tied to plan bids. Plans bear some risk for their enrollees’ drug spending.

### Approval of PDP Plans

Each year, CMS issues a call letter to sponsors planning to offer PDP and/or MA plans in the following year. The 2018 call letter, issued on April 3, 2017, combined updated contracting guidance and payment information for both programs.\(^{143}\)

Potential PDP and MA sponsors are required to submit bids by the first Monday in June of the year prior to the plan benefit year. The following information must be included as part of the bid: (1) coverage to be provided; (2) actuarial value of qualified prescription drug coverage in the region of a beneficiary with a national average risk profile; (3) information on the bid, including the basis for the actuarial value, the portion of the bid attributable to basic coverage and, if applicable, the portion attributable to enhanced coverage, and assumptions regarding the reinsurance subsidy; and (4) service area. The bid also includes costs (including administrative costs and return on investment/profit) for which the plan is responsible. The bid must exclude costs paid by enrollees, payments expected to be made by CMS for reinsurance, and any other costs for which the sponsor is not responsible. CMS reviews the information when negotiating with plan sponsors and in deciding whether to approve their program bids.

CMS may approve a drug plan only if certain requirements are met. For example, CMS must determine that the plan and sponsor meet requirements relating to actuarial determinations and beneficiary protections. The plan cannot be designed in a way (including any formulary or tiered formulary structure) that would likely discourage enrollment by certain beneficiaries.

If their bids are approved, PDP sponsors enter into 12-month contracts with CMS. A contract may cover more than one Part D plan. Under the terms of a contract, the sponsor agrees to comply with Part D requirements and have satisfactory administrative and management arrangements. Beginning in 2016, CMS imposed a two-year Part D application ban on sponsors that have been approved to offer PDP plans but withdraw their bids after CMS announces the annual LIS benchmark amounts.\(^{144}\)

---

\(^{141}\) The Part D sponsors are private entities licensed to offer health insurance under state law. Alternatively, they could meet solvency standards established by CMS for entities not licensed by the state.

\(^{142}\) If two or more plans are not available in a region (one of which is a PDP), Medicare is required to contract with a non-risk “fallback” plan to serve beneficiaries in that area. Because of the large number of Part D plans participating in the program, CMS has not needed to solicit bids from fallback contractors.


\(^{144}\) CMS, “CMS Finalizes Program Changes for Medicare Advantage and Prescription Drug Benefit Programs for
Noninterference Provision

The MMA, which created the Part D program, contains a provision that prohibits the HHS Secretary from interfering in negotiations on drug prices and from setting plan formularies. The provision states that “(i) in order to promote competition under this part and in carrying out this part, the Secretary: (1) may not interfere with the negotiations between drug manufacturers and pharmacies and PDP sponsors; and (2) may not require a particular formulary or institute a price structure for the reimbursement of covered Part D drugs.”

Plan Availability

For the 2018 plan year, sponsors offered 782 PDPs and 2,003 MA–PDs. The number of PDPs per region in 2018 range from a low of 19 to a high of 26 across the 34 Part D regions, and beneficiaries also typically have about 10 MA-PD options to choose from. Compared to 2017 plan offerings, the number of PDPs has risen by about 5%, while the number of MA-PDs has increased by about 16%.

Availability of Low-Income Plans

A Part D plan qualifies as a LIS benchmark plan if it offers basic Part D coverage and charges premiums that are equal to, or lower than, the average, regional low-income benchmark premium. Regional LIS benchmark premiums are recalculated annually, based on the weighted average of all premiums in each of the 34 PDP regions. The formula for determining the benchmark is based on premiums for basic prescription drug coverage, or the actuarial value of basic prescription drug coverage for plans that offer enhanced coverage. For MA-PD plans, the formula uses the portion of the premium attributable to basic prescription drug benefits.

In 2018, there are 216 LIS benchmark PDPs – the lowest number since Part D began. Florida has two benchmark plans, while the number of such plans ranges from 3 to 10 in other Part D regions. LIS beneficiaries enrolled in a plan that loses its benchmark status for a coming plan year either are enrolled automatically in a new plan by CMS or must select a new plan to avoid paying premiums and other cost-sharing requirements. (See “LIS Enrollment.”) As is the case for non-LIS enrollees, enrollment for LIS enrollees has become concentrated over time. In 2017, CVS Health had 2.4 million, or 20% of all LIS enrollees, in its Part D plans.

Plan Payments

Medicare provides a subsidy for each non-LIS Medicare enrollee in a Part D plan that is equal to 74.5% of average, standard coverage. The average subsidy takes two forms: direct subsidy
payments and reinsurance payments. Medicare also establishes risk corridors to limit a plan’s overall losses or profits. In addition, Medicare pays most of the cost sharing and premiums for LIS beneficiaries enrolled in PDP or MA-PD plans.

**Direct Subsidies**

Medicare makes monthly prospective payments (direct subsidies) to plans for each Part D enrollee. The payments are based on the nationwide average of plan bids for providing basic drug coverage, weighted by the plans’ share of total enrollment. (The national average monthly bid is $57.93 for plan year 2018.) The subsidy amount is risk-adjusted to account for the health status of the beneficiaries expected to enroll; plans with sicker enrollees receive a higher subsidy. The subsidy is further adjusted to cover expected, additional costs associated with LIS enrollees. Lastly, the payment is reduced by the base beneficiary premium for the plan. (See “Premiums.”)

**Reinsurance Subsidies**

As previously noted, in a standard drug plan, the Part D sponsor pays nearly all drug costs above a catastrophic threshold, except for nominal beneficiary cost sharing. Medicare subsidizes 80% of each plan’s costs for this catastrophic coverage – the reinsurance subsidy. (See “Part D Benefit Structure.”) Payments are made on a monthly basis during the year, based on either estimated or incurred costs, with final reconciliation made after the close of the year when plans have data on their actual costs. Medicare subsidies for reinsurance are now the largest component of Part D, and are also the fastest-growing portion of the program.

**Risk Corridor Payments**

The MMA also established risk corridors for Part D plans. Under the risk corridors, Medicare limits plan sponsors’ potential losses, or gains, by financing some higher-than-expected costs, or recouping some excessive profits, relative to the amount the plan originally bid to offer Part D. Risk corridors are based on a plan’s allowable costs (spending) relative to a percentage of its target amount (revenues), as defined below:

- Allowable costs are defined as costs (excluding administrative costs, but including costs directly related to drug dispensing) incurred by a plan sponsor or organization that are actually paid (net of discounts, chargebacks, and average percentage rebates from drug manufacturers) by the sponsor or organization. Plans may not include costs for benefits beyond the Part D basic benefit amount. The costs are reduced by the sum of reinsurance payments and low-income subsidy payments.

---

151 The calculation of the national average monthly bid amount does not include bids submitted by Medical Savings Account (MSA) plans, MA private fee-for-service plans, specialized MA plans for special needs populations (SNP), Program of All-Inclusive Care for the Elderly (PACE) plans, or plans established through reasonable cost contracts.


The target amount is defined as total payments to a plan (including amounts paid by both Medicare and enrollees) based on a plan’s standardized bid for offering the Part D drug benefit, as risk adjusted. The target amount does not include administrative expenses assumed in the plan’s standardized bid.

At the end of each year, CMS compares a Part D plan’s allowable costs to its target amount and shares in any gains or losses within a pre-determined range, or corridor. For plan year 2018, a plan that has higher-than-expected costs must cover all benefit spending up to 105% of its standardized bid. A plan with costs above 105% and up to 110% of its bid must cover 50% of the costs within this range and CMS will pay the other 50%. A plan with costs above 110% of the bid must pay 20% of this additional amount, with CMS covering the other 80%. Likewise, a plan that spends less than its standardized bid may keep all savings between 100% and 95% of the bid. A plan that has spending below 95% to 90% of its bid may keep 50% of the savings within this range, while rebating 50% to CMS. A plan with savings below 90% of the bid may keep 20% of the savings within this range and must rebate 80% to CMS.

As CMS has gained more experience with Part D, the risk corridors have widened, increasing the share of insurance risk borne by the plans. From 2008 to 2011, drug plans bore all gains and losses that fell within 5% of expected costs, compared with a smaller range of 2.5% of expected costs in 2006 and 2007.

Since 2012, CMS has had the authority under the MMA to either leave the corridors unchanged or to widen them. CMS has moved to keep the corridors at 2011 levels through the 2018 program year.

### Table 8. Plan Liability Under Part D Risk Corridor Provisions

<table>
<thead>
<tr>
<th>Risk Corridor</th>
<th>Plan Liability for Costs Above and Below Target</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>2006-2007</strong></td>
<td></td>
</tr>
<tr>
<td>Costs below 95% of target</td>
<td>80% refund</td>
</tr>
<tr>
<td>Costs between 95% and 97.5%</td>
<td>75% refund</td>
</tr>
<tr>
<td>Costs between 97.5% and 102.5%</td>
<td>Full risk</td>
</tr>
<tr>
<td>Costs between 102.5% and 105%</td>
<td>Risk for 25% of amount</td>
</tr>
<tr>
<td>Costs over 105% of target</td>
<td>Risk for 20% of amount</td>
</tr>
<tr>
<td><strong>2008-2018</strong></td>
<td></td>
</tr>
<tr>
<td>Costs below 90% of target</td>
<td>80% refund</td>
</tr>
<tr>
<td>Costs between 90% and 95%</td>
<td>50% refund</td>
</tr>
<tr>
<td>Costs between 95% and 105%</td>
<td>Full risk</td>
</tr>
<tr>
<td>Costs between 105% and 110%</td>
<td>Risk for 50% of amount</td>
</tr>
</tbody>
</table>

155 The plans’ standardized bid is their estimated cost of providing the standard Part D drug benefit. This bid is used in the calculation to determine plan payments.


157 Allowable costs include Part D drug costs minus the reinsurance subsidy and direct and indirect remuneration from drug manufacturers.

Reconciliation

Following the close of a calendar year, CMS makes retroactive adjustments to the direct subsidy payments made to plans to reflect actual plan experience. The direct subsidy payments are adjusted based on updated data about actual beneficiary health status and enrollment. Additionally, prospective payments for reinsurance and low-income subsidy payments are compared to actual incurred costs, net of any direct or indirect remuneration (including discounts, chargebacks or rebates from drug manufacturers), and other related data, and appropriate adjustments are made to the plan payments. Finally, any necessary adjustments are made to reflect risk sharing under the risk corridor provisions. In general, Part D plans have tended to overestimate their costs for operating Part D plans in the aggregate. For example, Part D plans each year have made net risk corridor payments to CMS. (See Table 9.)

CMS data on individual plans continue to show considerable variation in terms of risk-sharing, with some plans making significant risk corridor payments to CMS, and others requiring government payments.\textsuperscript{159} MedPAC has raised questions about whether Part D plans are adequately assessing risk in their annual plan bids, but suggested that keeping Part D risk corridors in place, at least temporarily, would help to limit excess plan profits.\textsuperscript{160}

\begin{table}
\centering
\caption{Medicare Part D Risk Corridor Payments}
\begin{tabular}{ll}
\hline
\textbf{Year} & \textbf{Net Risk-Sharing Payments} \\
\hline
2006 & -$1.6 \\
2007 & 0.5 \\
2008 & 0.2 \\
2009 & 0.7 \\
2010 & 0.1 \\
2011 & 0.9 \\
2012 & 1.1 \\
2013 & 0.7 \\
2014 & 0.1 \\
2015 & 1.1 \\
\hline
\end{tabular}
\end{table}


### Table

<table>
<thead>
<tr>
<th>Year</th>
<th>Net Risk-Sharing Payments</th>
</tr>
</thead>
<tbody>
<tr>
<td>2016</td>
<td>-1.1</td>
</tr>
<tr>
<td>2017</td>
<td>-0.9</td>
</tr>
<tr>
<td>2018</td>
<td>0.2</td>
</tr>
</tbody>
</table>

**Source:** 2018 Medicare Trustees Report, Table IV.B10, and 2016 Medicare Trustees Report, Table IV.B10.

**Notes:** Positive amounts represent net payments from CMS to Part D insurers, and negative amounts represent net payments from the plans to CMS. The amounts may include the delayed settlement of risk sharing from prior years. Figures for 2006 and 2007 include reimbursement of certain state costs under the Part D transition demonstration program. Figures for 2017 and 2018 are estimates; other years are actual data.

### Reduction of Part D Plan Payments Under Sequestration

Due to provisions in the Budget Control Act of 2011 (BCA; P.L. 112-25), most Medicare benefit related payments are being reduced through sequestration by 2%. Under Part D, Medicare payments to plans for the direct subsidies and retiree drug subsidies are being reduced by this amount. Payments for reinsurance, risk-sharing, and the low-income subsidy are exempt from these reductions. Part D plans are not permitted to increase beneficiary premiums or cost sharing, or reduce benefits in order to make up for their lower payments under sequestration. The sequestration of Medicare benefit spending is scheduled to continue through FY2027.

### Pharmacy Access and Payment

Part D sponsors are required to establish a pharmacy network sufficient to ensure access to covered Part D drugs for all enrollees. Sponsors must demonstrate that they provide (1) convenient access to retail pharmacies for all enrollees, (2) adequate access to home infusion pharmacies for all enrollees, (3) convenient access to long-term care (LTC) pharmacies for residents of LTC facilities, and (4) access to Indian Health Service, Tribes, or Urban Indian Programs pharmacies operating in the sponsor’s service area.

### Any Willing Pharmacy

Part D sponsors are required to permit any pharmacy that is willing to accept the sponsor’s standard contracting terms and conditions to participate in the plan’s network, including mail-order pharmacies. A sponsor’s standard terms and conditions, particularly reimbursement terms, may vary to accommodate geographic areas or types of pharmacies, so long as all similarly situated pharmacies are offered the same standard terms and conditions. A Part D sponsor may not require a network pharmacy to accept insurance risk as a condition of participation in its pharmacy network.

---

161 For additional information on sequestration and Medicare, see CRS Report R45106, *Medicare and Budget Sequestration*.


Beginning in 2019, Part D plans will be required to (1) make standard pharmacy contract terms and conditions available by September 15 of each year for contracts effective on January 1 of the following year, and (2) provide a copy of a standard contract to a requesting pharmacy within seven business days after receiving such a request from the pharmacy.164

Preferred Pharmacy

While any qualified pharmacy can participate in a plan network, Part D plans, with the exception of plans offering defined, standard coverage,165 may contract with a smaller subset of pharmacies, or pharmacy chains, to serve as preferred pharmacies.166 Preferred pharmacies generally are marketed as having lower beneficiary cost sharing than other pharmacies in the plan network. Beneficiaries who sign up for a preferred pharmacy plan still have the option of going to any one of a number of network pharmacies in their plan region, but may face a higher cost share to fill a prescription at a non-preferred pharmacy.167

The creation of a preferred pharmacy network must not increase overall CMS payments to a Part D plan.168 In addition, the cost differential between preferred and non-preferred pharmacies cannot be set at a level that discourages enrollees in certain locations, such as inner cities or rural areas, from enrolling in a Part D plan.

Retail Pharmacy Access

To ensure that enrollees have convenient access to covered drugs, Part D networks must include a sufficient number of pharmacies that dispense drugs directly to patients (other than by mail order).

CMS defines convenient access as follows:

- In urban areas, at least 90% of Medicare beneficiaries in a Part D sponsor’s service area, on average, live within two miles of a retail pharmacy participating in the sponsor’s network.
- In suburban areas, at least 90% of Medicare beneficiaries in the sponsor’s service area, on average, live within five miles of a retail pharmacy participating in the sponsor’s network.

---


165 Because cost sharing cannot be changed under defined standard coverage, such plans cannot have price differences based on the pharmacy used.

166 The rules are waived in certain instances, such as MA-PD plans that offer access to drugs through retail pharmacies owned and operated by the MA organization that offers the plan. See CMS, Medicare Prescription Drug Manual, Chapter 5, “Benefits and Beneficiary Protections,” Section 50.9, Rev. September 30, 2011, at http://www.cms.gov/Medicare/Prescription-Drug-Coverage/PrescriptionDrugCovContra/Downloads/MemoPDIManualChapter5_093011.pdf.

167 For more information, see CRS In Focus IF10037, Medicare Preferred Pharmacy Networks.

168 Ibid.
• In rural areas, at least 70% of Medicare beneficiaries in the sponsor’s service area, on average, live within 15 miles of a retail pharmacy participating in the sponsor’s network.\(^{169}\)

CMS has issued a definition of retail pharmacy, to take effect in 2019, to provide better guidance for Part D plans in determining which contracted pharmacies count toward meeting the convenient access standards.\(^{170}\) The definition of retail pharmacy will be “any licensed pharmacy that is open to dispense prescription drugs to the walk-in general public from which Part D enrollees could purchase a covered Part D drug without being required to receive medical services from a provider or institution affiliated with that pharmacy.”\(^{171}\)

**Mail-Order Pharmacy Access**

Part D plans have the option of including mail order pharmacies in their networks, though they cannot count such pharmacies in meeting retail pharmacy access requirements.\(^{172}\) Plan sponsors may offer a subset of formulary drugs (such as a particular tier of drugs or maintenance drugs) through mail-order pharmacies. If a Part D plan offers a mail-order pharmacy benefit (such as a 90-day supply of a maintenance drug) it must ensure that enrollees have reasonable access to the same benefit at retail network pharmacies. However, enrollees may be charged more by Part D sponsors for filling certain prescriptions at a retail pharmacy, rather than a mail-order pharmacy, within limits set by CMS.\(^{173}\)

**Specialty Pharmacy Access**

Part D plans may designate certain pharmacies as specialty pharmacies for the distribution of drugs where the FDA has restricted distribution of the drug to certain facilities or physicians or appropriate dispensing requires extraordinary special handling, provider coordination, or patient education that cannot be met by a network pharmacy. Part D plans may not require enrollees to use a specialty pharmacy to fill a prescription solely because a drug has been placed on a Part D

---


\(^{173}\) Ibid., Section 50.10. Sponsors may require an enrollee to pay higher cost sharing up to an amount equal to the mail-order cost sharing plus any differential in contracted rates between retail and mail-order, but plans may charge beneficiaries a lower cost sharing at retail if they so choose. Some pharmacies may ship drugs to patients in long-term care facilities or in rural areas. A pharmacy that makes some but not the predominance of its deliveries through the mail is not a mail-order pharmacy.
plan’s specialty drug tier. Specialty drug tier designation is based on cost ($670 per month in 2018), not on other special handling requirements.\footnote{Ibid. Section 50.3.}

CMS does not have a regulatory definition of specialty pharmacy. Plans may set their own definition and fee structure for specialty pharmacies and specialty networks, including preferred specialty networks. However, Part D pharmacy contracting conditions must be reasonable and relevant and must be applied consistently.

**Long-Term Care Pharmacy Access**

Part D sponsors must offer LTC pharmacy access to beneficiaries in LTC facilities. In meeting this requirement, plan sponsors must offer standard long-term care (LTC) pharmacy network contracts to all LTC pharmacies operating in their service area that request such contracts. The pharmacies must be able to meet performance and service criteria specified by CMS, as well as any standard terms and conditions established by the Part D sponsor for its network LTC pharmacies. Part D sponsors may not rely on out-of-network pharmacies to meet the LTC convenient access standards.

**Home Infusion Pharmacy Access**

Part D covers certain home-infusion drugs, which are prescription drugs that are given intravenously in a home setting. Administration of the drugs may require supplies and equipment such as tubing and catheters or special pumps. Part D plan sponsors must be able to deliver home-infusion drugs to plan enrollees within 24 hours after the enrollees are released from an acute care setting, unless the next dose of the medication is not due to be taken for more than 24 hours. (An acute care setting is a hospital, ambulatory care unit or similar facility where a patient receives treatment for a serious but brief illness). Part D plans are not expected to pay for supplies, equipment or professional services needed for home infusion therapy. They are expected to stock drugs in a form that can be easily used, to deliver products when needed, and to ensure that enrollees have the necessary supplies and professional assistance before dispensing home infusion drugs.

**Out-of-Network Access**

In general, a beneficiary must go to a pharmacy in his or her Part D network. However, in cases where enrollees cannot reasonably be expected to obtain covered drugs at a network pharmacy, and when such cases are not routine, a Part D plan must ensure that enrollees have adequate access to out-of-network pharmacies.\footnote{CMS, Medicare Prescription Drug Manual, Chapter 5, “Benefits and Beneficiary Protections,” Section 60, Rev. September 30, 2011, at http://www.cms.gov/Medicare/Prescription-Drug-Coverage/PrescriptionDrug Coverage/downloads/memopdbmanualchapter5_093011.pdf.} One example would be if a Part D enrollee were traveling in the United States, came down with an illness, and needed to have a prescription filled. Another possible scenario would be a federal disaster declaration in the case of major storm or other event, where a beneficiary was not able to use an in-network provider.

Part D plans must craft reasonable guidelines for out-of-network usage, and can set conditions such as requiring enrollees to order maintenance-type drugs from a mail-order pharmacy if they are going to be traveling for an extended period of time. In general, plans may not routinely allow more than a month’s worth of medication to be dispensed at an out-of-network pharmacy.
Enrollees will likely be required to pay more for a covered Part D drug purchased out of the plan network than one purchased at a network pharmacy.

Payments to Pharmacies

Plan sponsors negotiate with pharmacies to include a sufficient number and geographic distribution of pharmacies in their networks. A plan reimburses a pharmacy for the cost of a drug, plus a dispensing fee. Pharmacies set their own rates for dispensing drugs but may give a plan a discount from their usual rate.

The law requires Part D sponsors to make payment for “clean claims,” within 14 calendar days of the date when an electronic claim is received, and within 30 calendar days of the date that non-electronically submitted claims are received.\(^{176}\) A clean claim is a claim that does not require further development or investigation (for example, has all required documentation) or other special treatment that would prevent the claim from being paid in a timely manner. If payment is not issued, mailed, or otherwise transmitted within the applicable number of calendar days after a clean claim is received, the PDP sponsor or MA-PD plan will be required to pay interest to the pharmacy that submitted the claim.

Coverage Determinations, Appeals, and Grievances

Part D enrollees have the right to request or appeal coverage determinations, file grievances against plan sponsors, and file complaints regarding quality of care.\(^{177}\) PDPs and MA-PDs are required to provide enrollees with written information about their rights, and to institute both standard and expedited procedures for addressing coverage issues.\(^{178}\)

An enrollee may appoint a representative to act on his or her behalf during the grievance and appeals process such as a friend, relative, attorney, physician, or an employee of a pharmacy or a charity. To appoint a representative, an enrollee must submit a written statement to the drug plan sponsor.\(^{179}\) Alternatively, a surrogate or representative may be appointed by a court or authorized under a state or other applicable law to act on behalf of an enrollee. A prescribing physician or other prescriber may request a standard or expedited coverage determination, redetermination, or independent review entity (IRE) reconsideration on behalf of an enrollee without being named a representative.\(^{180}\) (Physicians or prescribers do not have all the rights of a designated representative, however, unless they have gone through the formal appointment process.)

\(^{176}\) This provision was added by MIPPA and may be found at §1860D-12(b)(4)(A)(ii) of the Social Security Act.

\(^{177}\) CMS, Medicare Appeals, at http://www.medicare.gov/Pubs/pdf/11525.pdf.


\(^{179}\) An enrollee may request a representative by using a government form (Form CMS-1696) or by submitting an equivalent written notice that includes information about enrollee and is signed and dated by both the enrollee and the representative. There are exceptions in the case of institutionalized or incapacitated enrollees.

Coverage Determination

A coverage determination is any decision (whether an approval or denial) made by a plan sponsor with regard to covered benefits. Examples of coverage determinations include (1) a decision about whether to provide or pay for a Part D drug that an enrollee believes may be covered;\(^ {181}\) (2) a decision concerning a request about a specific drug payment tier;\(^ {182}\) (3) a decision concerning a request to cover a drug that is not included on a plan formulary; (4) a decision regarding cost-sharing levels; or (5) a decision regarding whether an enrollee has satisfied a prior authorization or other utilization management requirement. An enrollee, an enrollee’s appointed representative, or his or her physician may file a request for a coverage determination.\(^ {183}\)

An enrollee may also request an expedited decision regarding a drug that has not already been furnished. The plan is to make a decision within 24 hours in cases where using the standard timeframe may seriously jeopardize the life or health of the enrollee or the enrollee’s ability to regain maximum function. A Part D sponsor that approves a request for expedited determination must make its determination and notification, whether adverse or favorable, as expeditiously as the enrollee’s health condition requires, but no later than within 24 hours.

If a Part D plan sponsor denies a request for an expedited determination, it must:\(^ {184}\)

- make the determination within the 72-hour timeframe established for a standard determination; and
- give the enrollee and prescribing physician or other prescriber prompt oral notice of the denial.

If a sponsor fails to notify the beneficiary of its decision within the established time frames, the decision is deemed an automatic denial, at which point the sponsor must forward the case to the independent review entity, the second level of appeal.

Appeals

If a plan sponsor’s coverage determination is unfavorable, it must provide the affected enrollee with a written denial notice that includes information on appeals rights. An appeal is a request for a further review of a coverage determination.\(^ {185}\) There are five levels of appeals.

Redetermination

The first level of appeal is a redetermination by the plan. An enrollee, enrollee’s representative or enrollee’s prescribing physician or other prescriber may request a standard or expedited

---

181 This includes a decision not to pay because the drug is not on the plan’s formulary, the drug is determined not medically necessary, or the drug is furnished by an out-of-network pharmacy.
182 MMA provided that if a Part D plan includes a tiered cost-sharing structure, a plan enrollee can request an exception to the structure. Under an exception, a non-preferred drug could be covered as a preferred drug if the prescribing physician determined that the preferred drug for treatment of the same condition would not be as effective for the individual, would have adverse effects for the individual, or both.
184 Ibid.
185 Individuals can appeal coverage determinations related to formulary drugs and non-formulary drugs. They cannot appeal denial of coverage for excluded drugs.
redetermination by filing a written request with the plan sponsor. The request generally must be filed within 60 calendar days from the date printed or written on the written coverage determination denial notice. If a physician asks for, or supports, an expedited appeal on the grounds that waiting seven days could seriously harm an enrollee’s health, the appeal is to automatically be expedited.\(^{186}\)

Plan sponsors must provide immediate access to the redetermination process through their websites. CMS strongly encourages plans to establish interactive, web-based systems to meet this requirement.

A plan sponsor must also provide an enrollee or prescribing physician with a reasonable opportunity to present evidence, and the redetermination must be made by a person not involved in the original coverage decision.\(^{187}\) Enrollees are to be notified of the results within 7 days in the case of standard redetermination or within 72 hours for an expedited request. Beginning in 2019, plans will have 14 days to respond to a standard redetermination. The timeline for an expedited request will remain the same.\(^{188}\)

### Reconsideration by an Independent Review Entity

At the second level of appeal, an enrollee dissatisfied with a redetermination has a right to reconsideration by an independent review entity (IRE) working under contract with CMS, also known as a Qualified Independent Contractor (QIC). An enrollee or an enrollee’s appointed representative may request a standard or expedited reconsideration. The request must be made within 60 days of a redetermination. The IRE is required to make a decision within 7 days for a standard reconsideration and 72 hours for an expedited reconsideration. Beginning in 2019, plans will have 14 days to respond to a standard reconsideration. The timeline for an expedited reconsideration will remain the same.\(^{189}\)

According to CMS, Medicare received 35,414 reconsideration cases in CY2016. In about 30% of the cases, the plan sponsor’s decision was overturned.\(^{190}\)

### Additional Levels of Appeal

If the above appeals result in decisions unfavorable to the enrollee, several additional levels of review may be pursued.

At the third level of appeal, an enrollee or the appointed representative may request a hearing with an administrative law judge (ALJ). A request must be made within 60 days of the IRE decision letter. To qualify for an ALJ hearing, the projected value of denied coverage must meet a


\(^{187}\) If the issue is the denial of coverage based on medical necessity, the redetermination must be made by a physician.


\(^{189}\) Ibid.

\(^{190}\) CMS, “Fact Sheet: Part D Reconsiderations Appeals Data-2016,” at CMS webpage “Reconsiderations by the Independent Review Entity,” at https://www.cms.gov/Medicare/Appeals-and-Grievances/MedPrescriptDrugApplGrie/Reconsiderations.html. Data exclude cases that were dismissed, withdrawn, or remanded (the Part D QIC did not have jurisdiction to make a substantive decision on the case) and cases involving non-Part D drugs. The Part D QIC reversed plan decisions in 29.81% of cases.
minimum dollar amount ($160 for 2018). An enrollee cannot request an expedited hearing if the only issue at question involves a request for payment of Part D drugs that have already been furnished. There is a 90-day limit for a regular decision and a 10-day limit for an expedited decision.

The fourth level of appeal is the Medicare Appeals Council (MAC). A beneficiary or the appointed representative may request a review by the MAC within 60 days of the ALJ decision. The MAC may grant or deny the request for review. If it grants the request, it may issue a final decision or dismissal, or remand the case to the ALJ with instructions on how to proceed with the case. The review is to be completed within 90 days for a regular review and 10 days for an expedited review.

**Standard Hearing**

The final appeal level is a federal district court. A beneficiary or the appointed representative may request a review by a federal court within 60 days of the MAC decision notice. To receive a review by the court, the projected value of denied coverage must be greater than or equal to a minimum dollar amount ($1,600 for 2018).

**Grievances**

Grievances are complaints or disputes other than those involving coverage determinations. Grievances may include such things as complaints about a plan’s customer service hours of operation, the time it takes to get a prescription filled, or a plan’s benefit design. A grievance may also include a complaint that a Part D plan refused to expedite a coverage determination or redetermination. A beneficiary with a grievance may file a complaint within 60 days of the event. Although CMS regulations do not require a Part D plan sponsor to consider a grievance that is filed after the 60-day deadline, the regulations do not prevent a plan sponsor from doing so on a case-by-case basis.

Plan sponsors are to respond in a timely manner. A Part D plan sponsor must respond to an enrollee grievance within 24 hours if it involves a refusal by the Part D plan to grant an enrollee’s request for an expedited coverage determination or an expedited redetermination and the enrollee has not yet purchased or received the drug in dispute. (Sometimes a complaint may involve both a grievance and a coverage determination.)

**Quality of Care Complaints**

Complaints regarding quality of care received by Part D enrollees may be resolved by the plan sponsor, but also may be handled through a separate process: the Quality Improvement Organization (QIO) process. The QIO program is implemented by a network of contractors throughout the United States that work with providers and beneficiaries to improve the quality of care.

---


193 42 C.F.R. §423.564.

194 42 C.F.R. §423.564.

195 Social Security Act, §1154(a)(14).
health care delivered to Medicare beneficiaries. When a Part D plan responds to an enrollee’s grievance in writing, it must include a description of the enrollee’s right to file a QIO grievance. Quality of care grievances filed with a QIO may be filed and investigated beyond the 60-day time frame.

Program Oversight

The size, nature, and complexity of the Medicare Part D program put it at particular risk for fraud, waste, and abuse. Some examples of program vulnerabilities that have been identified include drug diversion (redirecting prescription drugs, such as opioids, for illegal purposes); billing for drugs that are not dispensed; and inappropriate plan denials of covered drugs. A variety of entities are involved in oversight activities to ensure program compliance and identify potentially fraudulent activities.

CMS Oversight

CMS is responsible for preventing and detecting fraud and abuse in Medicare Part D and ensuring sponsors’ compliance with applicable requirements. CMS conducts a wide variety of oversight activities, such as bid reviews, marketing reviews, financial and accounting reviews, program audits, and LIS-readiness audits. Some of the management controls used in the routine operation of Medicare Part D play a primary role in the administration of the benefit and a secondary role in fraud prevention and detection.

For each plan sponsor, CMS establishes a point of contact (account manager) for all communications with the plan. The account managers are to work with plans to resolve any problems, including compliance issues. As part of its oversight strategy, CMS conducts routine program audits to ensure compliance with various program requirements, including such things as enrollment and disenrollment, marketing and beneficiary information, pharmacy access, coordination of benefits, claims processing and payment, and grievances and coverage determinations. CMS can also conduct separate, focused audits to confirm that a previously identified deficiency has been corrected or to check into an indication of non-compliance. These audits include a combination of desk and on-site activities.

In financial audits, CMS looks at the accuracy and validity of data reported by the plans. These audits, normally conducted after payment reconciliation, may examine things such as possible overpayments to plans, misrepresentation of bids, underreporting of rebates, and inaccurate prescription drug event data. If financial audits identify problems, CMS would recalculate payment reconciliation for that sponsor and target the sponsor for a future audit.


198 The only statutorily required activity is that CMS conduct financial audits of one-third of the plans each year. Social Security Act §1860D-12(b)(3)(C).

If egregious problems are identified, CMS actions can range from warning letters to civil monetary penalties or removal from the program, depending on the extent to which plans have violated Part D program requirements.

Oversight Responsibilities of Part D Sponsors

CMS requires plan sponsors to monitor and correct their own behavior, as well as the behavior of those they contract with. Part D sponsors are required by law to implement a comprehensive fraud and abuse program to detect, correct, and prevent fraud, waste, and abuse. Chapter 9 of CMS’s Prescription Drug Benefit Manual provides both interpretive rules and guidelines for sponsors to follow in developing this program.200

Part D sponsors are required to have, and to implement, an effective compliance plan as a condition of participation in the Medicare program. Elements of an effective plan include written policies and procedures; a designated compliance officer and committee; training and education, effective lines of communication, well-publicized disciplinary guidelines, and internal monitoring and auditing; and prompt response to detected offences and development of corrective actions.

Part D sponsors are also required to provide fraud, waste, and abuse training and education to first-tier, downstream, and related entities.201 This includes pharmacists, pharmacy clerks, and others who are employed by entities that plans contract with to provide the Medicare drug benefit.

Medicare Part D Oversight Contractors

Medicare Drug Integrity Contractor: National Benefit Integrity

CMS contracts with a private firm, Health Integrity Inc.,202 to act as the National Benefit Integrity Medicare Drug Integrity Contractor (NBI MEDIC) for Part D plans. The NBI MEDIC’s responsibilities include conducting complaint investigations; performing data analysis; developing and referring cases to law enforcement, as well as supporting ongoing investigations; conducting audits; and reviewing PDP and MA-PD fraud and abuse compliance programs.203

The NBI MEDIC is also responsible for working with other entities to coordinate fraud prevention and detection efforts, including the Part D sponsors, other Medicare contractors, the HHS Office of Inspector General (OIG), the Department of Justice, and state agencies.

Medicare Drug Integrity Contractor: Outreach and Education

CMS also has contracted with Rainmakers Strategic Solutions LLC204 to act as the Outreach and Education Medicare Drug Integrity Contractor (O&E MEDIC). The O&E MEDIC provides

---


201 Ibid.


education on waste, fraud, and abuse for plan sponsors, pharmacists, law enforcement, as well as for Medicare advocates and enrollees. The O&E MEDIC maintains a website containing fraud and abuse related regulations and guidance, professional education materials, and relevant state and federal agency contact information.

Part D Recovery Audit Contractor
The ACA required CMS to expand its Recovery Audit Contractor (RAC) program to Medicare Part C and Part D. CMS has contracted with ACLR Strategic Business Solutions to perform the Part D RAC audit functions. The Part D RAC reviews Medicare payments made to plan sponsors and pharmacies to identify any over- or underpayments, provides information to CMS to help prevent future improper payments, and refers potential fraud findings to the NBI MEDIC.

Program Spending and Financing
Medicare’s financial operations are accounted for through two trust funds maintained by the Department of the Treasury— the Hospital Insurance (HI) trust fund for Part A and the Supplementary Medical Insurance (SMI) trust fund, which contains separate accounts for Parts B and Part D. Unlike the HI program, SMI was not intended to be fully supported through dedicated sources of income. Instead, it relies primarily on general tax revenues and beneficiary premiums as revenue sources.

Expenditures
According to the 2018 Medicare Trustees Report, during CY2017, total Part D expenditures were approximately $100.0 billion. This amount included the combined costs of prescription drugs provided by Part D plans to enrollees and Medicare payments to employer-sponsored retiree health plans and federal administrative expenses, including expenses incurred by HHS, SSA, and the Department of the Treasury in administering Part D. Such duties include making payments to Part D plans and implementing fraud and abuse control activities. (See the Appendix for historical and projected Part D expenditures.)

Revenues
The major sources of revenue for the Part D account include general revenues, beneficiary premiums, and state contributions. In CY2017, of the $100.2 billion in total Part D income,  


207 This section was written by Patricia A. Davis, Specialist in Health Care Financing, Congressional Research Service.

208 The MMA established within the Supplementary Medical Insurance (SMI) Trust Fund the Medicare Prescription Drug Account to be used in conjunction with the Part D prescription drug program. For additional information on Medicare program financing, see CRS Report R43122, Medicare Financial Status: In Brief.

general revenues accounted for $73.2 billion, premiums accounted for $15.5 billion, and transfers from states for $11.4 billion.

The appropriation language adopted for the Part D account provides resources for benefit payments without the need for congressional approval. This allows substantial flexibility in the amount of general revenues available to the account, and eliminates the need for a contingency reserve. As a result, assets in the Part D account are generally low and only need to be held for a short time until they are used to meet immediate expenditures. As premium and general revenue income for Part D is reset each year to match expected costs, the Medicare Trustees consider the Part D account to be in satisfactory financial condition under current law.

**Beneficiary Premiums**

Beneficiary premiums are based on the participating plans’ national average bid amounts and are defined prior to each year’s operations, with the average premium amounting to 25.5% of the expected per capita plan costs for basic coverage. (See “Premiums.”) In 2018, the base monthly premium is $35.02; however, beneficiaries pay different premiums depending on the plan they selected (and whether they are entitled to low-income premium subsidies). Beneficiaries may have their premiums deducted from their Social Security or other federal benefit payments; these are then forwarded to Part D plans on their behalf. Alternatively, they may pay their premiums directly to the Part D plans.

As required by the ACA, since 2011, beneficiaries with higher incomes pay income-related monthly premium adjustments in addition to the premiums charged by the plans in which they have enrolled. (See “Premium Surcharge for Higher-Income Enrollees.”) These extra amounts are credited to the Part D trust fund account and reduce the amount of general revenue funding needed. Because individual plan premiums vary, the additional amount paid is calculated as a percentage of the base beneficiary premium, not the individual’s actual premium amount. This extra amount is usually deducted from an individual’s monthly Social Security payments regardless of how that person ordinarily pays the monthly prescription plan premiums. If the amount is greater than the monthly payment from Social Security, or an individual does not receive Social Security payments (e.g., the individual has not yet signed up for Social Security benefits), then CMS may directly bill the individual for this amount.

In CY2017, $5.0 billion in premium amounts were withheld from Social Security benefit checks or other federal benefit payments. (See Table 10.) Another $10.5 billion in premiums were paid directly to the plans by beneficiaries. As noted, premiums for the Part D program are generally set at an amount equal to 25.5% of standard benefit costs; however, as recipients of the Part D low-income subsidies are not required to pay premiums and premiums are based only on standard benefits (i.e., the premium calculation does not include such things as costs associated with the low-income subsidy and risk-corridor payments), premiums made up about 15.5% of total Part D program revenues in 2017.

---


211 The income thresholds are set at the same levels as those under Part B. For additional information, see Social Security Publication, Medicare Premiums: Rules for Higher-Income Beneficiaries, at http://www.ssa.gov/pubs/EN-05-10536.pdf.
General Revenues

General revenues are transferred from the Treasury to the Part D Account on an as-needed basis to cover the portion of program expenditures funded by federal subsidies. These transfers are based on expected costs of the direct subsidy, reinsurance payments, employer subsidies, low-income subsidies, net risk-sharing payments, administrative expenses, and advanced discount payments.\(^{212}\) In CY2017, contributions received from the general fund of the Treasury amounted to $73.2 billion, or about 73% of total Part D revenue.

### Table 10. Statement of Operations of Part D Account, CY2017

(\text{in millions of dollars})

\[
\begin{array}{lcc}
\hline
\text{Assets at Beginning of Year} & \$7,597.8 \\
\text{Revenues} & \$100,170.7 \\
\text{Premiums from Enrollees} & 15,493.8 \\
\text{Premiums deducted from Social Security checks} & 5,022.8 \\
\text{Premiums paid directly to plans} & 10,471.0 \\
\text{Government Contributions} & 73,217.4 \\
\text{Prescription drug benefits} & 73,342.6 \\
\text{Administrative expenses} & -125.1 \\
\text{Payments from States} & 11,405.8 \\
\text{Interest} & 53.6 \\
\text{Expenditures} & \$99,977.5 \\
\text{Benefit Payments} & 100,102.6 \\
\text{Federal Administrative Expenses} & -125.1 \\
\hline
\text{Assets at End of Year} & \$7,791.0 \\
\hline
\end{array}
\]

\text{Source: 2018 Medicare Trustees Report, Table III.D1.}

\text{Note: Totals may not add due to rounding.}

State Contributions

Subsequent to the availability of Part D drug coverage and low-income subsidies in 2006, Medicaid is no longer the primary payer of drug costs for full-benefit dual-eligible beneficiaries. However, MMA contained a provision (labeled by some as the “clawback provision”) that requires states to pay the Part D account in the SMI trust fund a portion of the costs that they would have incurred for this population if they were still the primary payer. These amounts are based on the product of the estimated annual per capita full dual-eligible drug payment amount and the monthly State enrollment of full dual eligibles.

Starting in 2006, states paid 90% of these estimated costs. This percentage phased down over a 10-year period to 75% starting in 2015. In CY2017, state payments amounted to $11.4 billion, or about 11.3% of Part D revenues.

\(^{212}\) Beginning in 2011, prescription drug manufacturers of brand name drugs provide a discount for their drugs when used during the coverage gap. Medicare makes payments prospectively to non-employer Part D plan sponsors and is reimbursed for these amounts once the sponsors receive the discounts from the manufacturers. This discount reduces beneficiary out-of-pocket costs, but has little net effect on federal Part D spending.
Historical Program Spending

Actual spending for the Medicare prescription drug benefit has been lower than estimated at the beginning of the program. The 2004 Medicare Trustees Report, the first of such reports issued subsequent to the enactment of MMA, projected that total program spending would be $85 billion in CY2006 (the first year of the program) and would grow to about $162 billion by CY2013.\(^{213}\) Actual Medicare expenditures for the Part D drug benefit were approximately $47 billion in CY2006 and close to $70 billion in CY2013. The difference between projected and actual spending has been due to both lower than expected enrollment and per capita spending. (See Table 11.) Original CBO estimates of Part D spending were also higher than actual spending for FY2004-FY2013. (See Table 12.)

Table 11. Comparison of Projected and Actual Part D Enrollment and Spending (CY2006-CY2013)

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>2006</td>
<td>40,736</td>
<td>30,560</td>
<td>$2,069</td>
<td>$1,708</td>
<td>$85.0</td>
</tr>
<tr>
<td>2007</td>
<td>41,468</td>
<td>31,392</td>
<td>2,225</td>
<td>1,556</td>
<td>93.0</td>
</tr>
<tr>
<td>2008</td>
<td>42,296</td>
<td>32,589</td>
<td>2,391</td>
<td>1,504</td>
<td>101.9</td>
</tr>
<tr>
<td>2009</td>
<td>43,158</td>
<td>33,644</td>
<td>2,557</td>
<td>1,798</td>
<td>111.2</td>
</tr>
<tr>
<td>2010</td>
<td>44,069</td>
<td>34,772</td>
<td>2,725</td>
<td>1,775</td>
<td>120.9</td>
</tr>
<tr>
<td>2011</td>
<td>45,117</td>
<td>35,720</td>
<td>2,892</td>
<td>1,868</td>
<td>131.4</td>
</tr>
<tr>
<td>2012</td>
<td>46,374</td>
<td>37,448</td>
<td>3,120</td>
<td>1,776</td>
<td>145.6</td>
</tr>
<tr>
<td>2013</td>
<td>47,761</td>
<td>39,103</td>
<td>3,367</td>
<td>1,772</td>
<td>161.8</td>
</tr>
</tbody>
</table>

Source: CRS analysis of data from Tables II.A3, II.C18 and II.C19 of the 2004 Medicare Trustees Report and Tables V.B4, III.D3 and III.D4 of the 2016 Medicare Trustees Report.

a. All data from the 2004 report are projected.
b. All data from the 2016 report are actual.

\(^{213}\) Original spending projections were made for the 10-year period 2004 to 2013. The Medicare Trustees report on a calendar year basis, while CBO reports on a fiscal year basis.
(in billions of dollars)

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Federal Spending</td>
<td>CBO Original Cost Estimate</td>
<td>$0.6</td>
<td>$1.5</td>
<td>$32.1</td>
<td>$52.9</td>
<td>$59.9</td>
<td>$65.7</td>
<td>$72.6</td>
<td>$79.5</td>
<td>$88.5</td>
<td>$98.9</td>
</tr>
<tr>
<td></td>
<td>2016 Medicare Trustees Report</td>
<td>0.2</td>
<td>1.2</td>
<td>27.7</td>
<td>41.5</td>
<td>35.4</td>
<td>43.5</td>
<td>52.7</td>
<td>57.0</td>
<td>44.5</td>
<td>50.1</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>35.9% less</td>
</tr>
<tr>
<td>Total Spending</td>
<td>CBO Original Cost Estimate</td>
<td>0.6</td>
<td>1.5</td>
<td>46.8</td>
<td>74.8</td>
<td>84.2</td>
<td>92.0</td>
<td>101.3</td>
<td>110.6</td>
<td>122.8</td>
<td>136.8</td>
</tr>
<tr>
<td></td>
<td>2016 Medicare Trustees Report</td>
<td>0.2</td>
<td>1.2</td>
<td>33.9</td>
<td>52.4</td>
<td>47.2</td>
<td>56.8</td>
<td>63.8</td>
<td>71.0</td>
<td>61.0</td>
<td>68.3</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>40.9% less</td>
</tr>
</tbody>
</table>


a. The figures in this table are for fiscal years, whereas those in Table 13 are for calendar years. Original projections were for the 10-year period FY2004 through FY2013.

b. Actual federal Medicare Part D cost is measured as total expenditures less premium income and transfers from states. Trustee report figures for FY2004-FY2013 reflect actual spending.

While aggregate Part D expenditures have increased by an average annual rate of 7.4% over the past 10 years (2008-2017), most of this growth reflects the growth in enrollment during the initial years of the program. Per capita expenditures during this time increased at a much slower annual rate of 3.8%. Both the Medicare Trustees and CBO attribute the slower per capita growth rate to a high proportion of prescriptions filled with low-cost generic drugs, as well as to patent expirations of major drugs during this period.214

In their 2018 report, the Medicare Trustees noted that 2017 Part D per capita benefit expenditures were lower than in 2016, and attributed this decrease to an increase in plan rebates and a reduction in hepatitis C drug spending.215 The Trustees expect this decline to continue in 2018, for the similar reasons. (See Table 13.)

**Estimated Future Part D Expenditures**

Over the next 10 years (2018-2027), the Medicare Trustees project more rapid growth in Part D costs, with aggregate benefits increasing on average at 6.9% annually, and per capita expenditures


increasing on average by 3.9% each year. This projected growth is due to expectations of further increases in the number of enrollees, changes in the distribution of enrollees among coverage categories (e.g., a movement from subsidized retiree plans to regular Part D plans and growth in the number of people reaching the catastrophic coverage level), a slowing of the trend toward greater generic drug utilization, and an increase in the use and the prices of specialty drugs. (See Table 13 and Table 14.)

### Table 13. Historical and Projected Growth in Part D Benefits

<table>
<thead>
<tr>
<th>Calendar Year</th>
<th>Aggregate Benefits (Billions)</th>
<th>Percentage Change</th>
<th>Per Capita Benefits</th>
<th>Percentage Change</th>
<th>Part D Benefits as a Percentage of GDP</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Historical data</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2004</td>
<td>$0.4</td>
<td>—</td>
<td>$362</td>
<td>—</td>
<td>0.00%</td>
</tr>
<tr>
<td>2005</td>
<td>1.1</td>
<td>—</td>
<td>596</td>
<td>—</td>
<td>0.01</td>
</tr>
<tr>
<td>2006</td>
<td>47.1</td>
<td>—</td>
<td>1,708</td>
<td>—</td>
<td>0.34</td>
</tr>
<tr>
<td>2007</td>
<td>48.8</td>
<td>3.7%</td>
<td>1,556</td>
<td>−8.9%</td>
<td>0.34</td>
</tr>
<tr>
<td>2008</td>
<td>49.0</td>
<td>0.4%</td>
<td>1,504</td>
<td>−3.3</td>
<td>0.33</td>
</tr>
<tr>
<td>2009</td>
<td>60.5</td>
<td>23.4%</td>
<td>1,798</td>
<td>19.6</td>
<td>0.42</td>
</tr>
<tr>
<td>2010</td>
<td>61.7</td>
<td>2.0%</td>
<td>1,775</td>
<td>−1.3</td>
<td>0.41</td>
</tr>
<tr>
<td>2011</td>
<td>66.7</td>
<td>8.1%</td>
<td>1,868</td>
<td>5.3</td>
<td>0.43</td>
</tr>
<tr>
<td>2012</td>
<td>66.5</td>
<td>−0.4%</td>
<td>1,776</td>
<td>−5.0</td>
<td>0.41</td>
</tr>
<tr>
<td>2013</td>
<td>69.3</td>
<td>4.2%</td>
<td>1,772</td>
<td>−0.2</td>
<td>0.42</td>
</tr>
<tr>
<td>2014</td>
<td>77.7</td>
<td>12.1%</td>
<td>1,919</td>
<td>8.3</td>
<td>0.45</td>
</tr>
<tr>
<td>2015</td>
<td>89.5</td>
<td>15.1%</td>
<td>2,140</td>
<td>11.5</td>
<td>0.49</td>
</tr>
<tr>
<td>2016</td>
<td>99.5</td>
<td>11.2%</td>
<td>2,302</td>
<td>7.6</td>
<td>0.53</td>
</tr>
<tr>
<td>2017</td>
<td>100.1</td>
<td>0.6%</td>
<td>2,252</td>
<td>−2.2</td>
<td>0.52</td>
</tr>
<tr>
<td><strong>Intermediate Estimates</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2018</td>
<td>94.1</td>
<td>−6.0%</td>
<td>2,057</td>
<td>−8.7</td>
<td>0.46</td>
</tr>
<tr>
<td>2019</td>
<td>103.3</td>
<td>9.8%</td>
<td>2,189</td>
<td>6.4</td>
<td>0.49</td>
</tr>
<tr>
<td>2020</td>
<td>113.3</td>
<td>9.7%</td>
<td>2,322</td>
<td>6.1</td>
<td>0.51</td>
</tr>
<tr>
<td>2021</td>
<td>122.7</td>
<td>8.3%</td>
<td>2,436</td>
<td>4.9</td>
<td>0.53</td>
</tr>
<tr>
<td>2022</td>
<td>133.6</td>
<td>8.9%</td>
<td>2,570</td>
<td>5.5</td>
<td>0.55</td>
</tr>
<tr>
<td>2023</td>
<td>144.7</td>
<td>8.3%</td>
<td>2,703</td>
<td>5.2</td>
<td>0.57</td>
</tr>
<tr>
<td>2024</td>
<td>156.6</td>
<td>8.2%</td>
<td>2,848</td>
<td>5.4</td>
<td>0.59</td>
</tr>
<tr>
<td>2025</td>
<td>167.3</td>
<td>6.8%</td>
<td>2,963</td>
<td>4.1</td>
<td>0.60</td>
</tr>
<tr>
<td>2026</td>
<td>180.7</td>
<td>8.0%</td>
<td>3,124</td>
<td>5.4</td>
<td>0.62</td>
</tr>
<tr>
<td>2027</td>
<td>194.7</td>
<td>7.7%</td>
<td>3,293</td>
<td>5.4</td>
<td>0.64</td>
</tr>
</tbody>
</table>

**Source:** 2018 Medicare Trustees Report, Table III.D4

---

216 Ibid., pp. 106.
Notes: Amounts shown are on a cash basis.

a. This amount does not include administrative expenses. See Table A-1 for data on total Part D expenditures.

Table 14. Medicare Part D Reimbursement Amounts

(in billions of dollars)

<table>
<thead>
<tr>
<th>Calendar Year</th>
<th>Direct Subsidy&lt;sup&gt;a&lt;/sup&gt;</th>
<th>Reinsurance</th>
<th>Low-Income Subsidy</th>
<th>Retiree Drug Subsidy</th>
<th>Total&lt;sup&gt;b&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Amount</td>
<td>Percentage</td>
<td>Amount</td>
<td>Percentage</td>
<td>Amount</td>
</tr>
<tr>
<td>Historical Data</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2006</td>
<td>$16.00</td>
<td>39.2%</td>
<td>$6.0</td>
<td>14.7%</td>
<td>$15.0</td>
</tr>
<tr>
<td>2007</td>
<td>17.6</td>
<td>38.1%</td>
<td>8.0</td>
<td>17.3%</td>
<td>16.7</td>
</tr>
<tr>
<td>2008</td>
<td>17.5</td>
<td>35.9%</td>
<td>9.4</td>
<td>19.3%</td>
<td>18.1</td>
</tr>
<tr>
<td>2009</td>
<td>18.2</td>
<td>35.1%</td>
<td>10.1</td>
<td>19.5%</td>
<td>19.6</td>
</tr>
<tr>
<td>2010</td>
<td>19.6</td>
<td>35.1%</td>
<td>11.2</td>
<td>20.1%</td>
<td>21.1</td>
</tr>
<tr>
<td>2011</td>
<td>19.2</td>
<td>32.7%</td>
<td>13.7</td>
<td>23.3%</td>
<td>22.2</td>
</tr>
<tr>
<td>2012</td>
<td>19.7</td>
<td>32.5%</td>
<td>15.5</td>
<td>25.5%</td>
<td>22.5</td>
</tr>
<tr>
<td>2013</td>
<td>19.6</td>
<td>30.8%</td>
<td>19.2</td>
<td>30.1%</td>
<td>23.2</td>
</tr>
<tr>
<td>2014</td>
<td>18.5</td>
<td>25.9%</td>
<td>27.2</td>
<td>38.1%</td>
<td>24.3</td>
</tr>
<tr>
<td>2015</td>
<td>18.1</td>
<td>23.2%</td>
<td>33.2</td>
<td>42.6%</td>
<td>25.6</td>
</tr>
<tr>
<td>2016</td>
<td>17.1</td>
<td>21.4%</td>
<td>35.5</td>
<td>44.4%</td>
<td>26.4</td>
</tr>
<tr>
<td>2017</td>
<td>14.2</td>
<td>17.8%</td>
<td>37.4</td>
<td>46.8%</td>
<td>27.5</td>
</tr>
<tr>
<td>Intermediate Estimate</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2018</td>
<td>13.5</td>
<td>16.4%</td>
<td>39.3</td>
<td>47.6%</td>
<td>28.9</td>
</tr>
<tr>
<td>2019</td>
<td>13.2</td>
<td>15.0%</td>
<td>43.0</td>
<td>48.9%</td>
<td>31.0</td>
</tr>
<tr>
<td>2020</td>
<td>14.5</td>
<td>15.1%</td>
<td>48.6</td>
<td>50.7%</td>
<td>32.2</td>
</tr>
<tr>
<td>2021</td>
<td>15.6</td>
<td>14.9%</td>
<td>53.5</td>
<td>51.2%</td>
<td>34.7</td>
</tr>
<tr>
<td>2022</td>
<td>16.7</td>
<td>14.7%</td>
<td>58.5</td>
<td>51.5%</td>
<td>37.7</td>
</tr>
<tr>
<td>2023</td>
<td>18.0</td>
<td>14.6%</td>
<td>63.6</td>
<td>51.7%</td>
<td>40.7</td>
</tr>
<tr>
<td>2024</td>
<td>19.3</td>
<td>14.5%</td>
<td>69.0</td>
<td>51.9%</td>
<td>43.9</td>
</tr>
<tr>
<td>2025</td>
<td>20.4</td>
<td>14.4%</td>
<td>73.9</td>
<td>52.1%</td>
<td>46.7</td>
</tr>
<tr>
<td>2026</td>
<td>21.8</td>
<td>14.2%</td>
<td>80.2</td>
<td>52.3%</td>
<td>50.4</td>
</tr>
<tr>
<td>2027</td>
<td>23.0</td>
<td>13.9%</td>
<td>86.8</td>
<td>52.6%</td>
<td>54.3</td>
</tr>
</tbody>
</table>

Source: CRS analysis based on data in the 2016 and 2018 Medicare Trustees Reports, Table IV.B10.

Notes: Amounts shown are on an incurred basis.

a. The direct subsidy amount shown is net of risk-sharing payments.

b. The total amounts do not include premiums paid by beneficiaries.

The Medicare Trustees project that total Part D expenditures will more than double during the next 10 years, from $94.5 billion in 2018 to $195.3 billion in 2027. (See Table A-1.) Annual per capita Part D benefit expenditures are also projected to increase—from $2,057 in 2018 to $3,293
in 2027. Over the longer term, the Trustees project that total Part D spending will grow from 0.48% of GDP in 2017, to 0.64% in 2027 and to 1.16% of GDP in 2092.  

---

217 Ibid., Table III.D4.
218 Ibid., Tables III.D4 and III.D6. GDP projection estimates are reported on an incurred basis.
## Appendix. Historical and Projected Part D Operations

### Table A-1. Operation of the Part D Account in the SMI Trust Fund, CY2004-CY2027

(in billions of dollars)

<table>
<thead>
<tr>
<th>Year</th>
<th>Premiums</th>
<th>General Revenue</th>
<th>Transfers from States</th>
<th>Total</th>
<th>Benefit Payments</th>
<th>Admin. Expenses</th>
<th>Total</th>
<th>Net Change</th>
<th>Balance at End of Year</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Historical Data</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2004</td>
<td>—</td>
<td>$0.4</td>
<td>—</td>
<td>$0.4</td>
<td>$0.4</td>
<td>—</td>
<td>$0.4</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>2005</td>
<td>—</td>
<td>1.1</td>
<td>—</td>
<td>1.1</td>
<td>1.1</td>
<td>—</td>
<td>1.1</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>2006</td>
<td>$3.5</td>
<td>39.2</td>
<td>$5.5</td>
<td>48.2</td>
<td>47.1</td>
<td>$0.3</td>
<td>47.4</td>
<td>$0.8</td>
<td>$0.8</td>
</tr>
<tr>
<td>2007</td>
<td>4.1</td>
<td>38.8</td>
<td>6.9</td>
<td>49.7</td>
<td>48.8</td>
<td>0.9</td>
<td>49.7</td>
<td>0.0</td>
<td>0.8</td>
</tr>
<tr>
<td>2008</td>
<td>5.0</td>
<td>37.3</td>
<td>7.1</td>
<td>49.4</td>
<td>49.0</td>
<td>0.3</td>
<td>49.3</td>
<td>0.1</td>
<td>0.9</td>
</tr>
<tr>
<td>2009</td>
<td>6.3</td>
<td>47.1</td>
<td>7.6</td>
<td>61.0</td>
<td>60.5</td>
<td>0.3</td>
<td>60.8</td>
<td>0.1</td>
<td>1.1</td>
</tr>
<tr>
<td>2010</td>
<td>6.5</td>
<td>51.1</td>
<td>4.0</td>
<td>61.7</td>
<td>61.7</td>
<td>0.4</td>
<td>62.1</td>
<td>-0.4</td>
<td>0.7</td>
</tr>
<tr>
<td>2011</td>
<td>7.7</td>
<td>52.6</td>
<td>7.1</td>
<td>67.4</td>
<td>66.7</td>
<td>0.4</td>
<td>67.1</td>
<td>0.3</td>
<td>1.0</td>
</tr>
<tr>
<td>2012</td>
<td>8.3</td>
<td>50.1</td>
<td>8.4</td>
<td>66.9</td>
<td>66.5</td>
<td>0.4</td>
<td>66.9</td>
<td>0.0</td>
<td>1.0</td>
</tr>
<tr>
<td>2013</td>
<td>9.9</td>
<td>51.0</td>
<td>8.8</td>
<td>69.7</td>
<td>69.3</td>
<td>0.4</td>
<td>69.7</td>
<td>0.0</td>
<td>1.0</td>
</tr>
<tr>
<td>2014</td>
<td>11.4</td>
<td>58.1</td>
<td>8.7</td>
<td>78.2</td>
<td>77.7</td>
<td>0.4</td>
<td>78.1</td>
<td>0.1</td>
<td>1.1</td>
</tr>
<tr>
<td>2015</td>
<td>12.8</td>
<td>68.4</td>
<td>8.9</td>
<td>90.0</td>
<td>89.5</td>
<td>0.3</td>
<td>89.8</td>
<td>0.3</td>
<td>1.3</td>
</tr>
<tr>
<td>2016</td>
<td>13.8</td>
<td>82.4</td>
<td>10.0</td>
<td>106.2</td>
<td>99.5</td>
<td>0.5</td>
<td>99.9</td>
<td>6.3</td>
<td>7.6</td>
</tr>
<tr>
<td>2017</td>
<td>15.5</td>
<td>73.2</td>
<td>11.4</td>
<td>100.2</td>
<td>100.1</td>
<td>-0.1</td>
<td>100.0</td>
<td>0.2</td>
<td>7.8</td>
</tr>
<tr>
<td><strong>Intermediate Estimates</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2018</td>
<td>15.8</td>
<td>66.2</td>
<td>11.8</td>
<td>93.8</td>
<td>94.1</td>
<td>0.4</td>
<td>94.5</td>
<td>-0.7</td>
<td>7.1</td>
</tr>
<tr>
<td>2019</td>
<td>16.6</td>
<td>75.3</td>
<td>12.3</td>
<td>104.2</td>
<td>103.3</td>
<td>0.4</td>
<td>103.7</td>
<td>0.5</td>
<td>7.6</td>
</tr>
<tr>
<td>2020</td>
<td>19.0</td>
<td>82.3</td>
<td>13.2</td>
<td>114.5</td>
<td>113.3</td>
<td>0.4</td>
<td>113.7</td>
<td>0.7</td>
<td>8.3</td>
</tr>
<tr>
<td>2021</td>
<td>20.3</td>
<td>89.2</td>
<td>14.4</td>
<td>139.9</td>
<td>123.9</td>
<td>0.5</td>
<td>123.2</td>
<td>0.7</td>
<td>9.1</td>
</tr>
<tr>
<td>2022</td>
<td>22.6</td>
<td>96.6</td>
<td>15.7</td>
<td>134.9</td>
<td>133.6</td>
<td>0.5</td>
<td>134.1</td>
<td>0.8</td>
<td>9.9</td>
</tr>
<tr>
<td>2023</td>
<td>24.6</td>
<td>104.3</td>
<td>17.1</td>
<td>146.0</td>
<td>144.7</td>
<td>0.5</td>
<td>145.2</td>
<td>0.8</td>
<td>10.7</td>
</tr>
<tr>
<td>2024</td>
<td>26.8</td>
<td>112.7</td>
<td>18.6</td>
<td>158.0</td>
<td>156.6</td>
<td>0.5</td>
<td>157.2</td>
<td>0.9</td>
<td>11.6</td>
</tr>
<tr>
<td>2025</td>
<td>28.7</td>
<td>119.8</td>
<td>20.1</td>
<td>168.6</td>
<td>167.3</td>
<td>0.5</td>
<td>167.8</td>
<td>0.8</td>
<td>12.4</td>
</tr>
<tr>
<td>2026</td>
<td>31.7</td>
<td>128.9</td>
<td>21.7</td>
<td>182.3</td>
<td>180.7</td>
<td>0.6</td>
<td>181.3</td>
<td>1.0</td>
<td>13.4</td>
</tr>
<tr>
<td>2027</td>
<td>33.3</td>
<td>139.8</td>
<td>23.3</td>
<td>196.4</td>
<td>194.7</td>
<td>0.6</td>
<td>195.3</td>
<td>1.1</td>
<td>14.5</td>
</tr>
</tbody>
</table>

**Source:** 2018 Medicare Trustees Report, Table III.D3.

**Notes:** Sums may not equal totals due to rounding. Some of the fluctuation in year by year spending is due to the payment structure of the Part D program. For example, in 2006, plan bids and therefore payments were
higher than actual spending; the $4 billion in reconciliation payments resulted in lower per capita Part D spending in 2007 and 2008. The Medicare Trustees expect that in 2017, plan bids will have exceeded spending by about $2 billion, and reconciliation payments in that amount will need to be paid by the plans to Part D in 2018.

Author Contact Information

Suzanne M. Kirchhoff
Analyst in Health Care Financing
skirchhoff@crs.loc.gov, 7-0658